EP0368684B2
(de)
*
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
US5872215A
(en)
*
|
1991-12-02 |
1999-02-16 |
Medical Research Council |
Specific binding members, materials and methods
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
WO1993019172A1
(en)
*
|
1992-03-24 |
1993-09-30 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5837242A
(en)
*
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
GB9225453D0
(en)
*
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
AU690171B2
(en)
*
|
1993-12-03 |
1998-04-23 |
Medical Research Council |
Recombinant binding proteins and peptides
|
ES2247204T3
(es)
|
1994-01-31 |
2006-03-01 |
Trustees Of Boston University |
Bancos de anticuerpos policlonales.
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6706484B1
(en)
|
1995-08-18 |
2004-03-16 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
ES2176484T3
(es)
*
|
1995-08-18 |
2002-12-01 |
Morphosys Ag |
Bancos de proteinas/(poli)peptidos.
|
GB9601081D0
(en)
*
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
US7368111B2
(en)
*
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
GB9621295D0
(en)
*
|
1995-12-07 |
1996-11-27 |
Cambridge Antibody Tech |
Specific binding members,materials and methods
|
WO1997022972A2
(en)
*
|
1995-12-15 |
1997-06-26 |
Pharmacia & Upjohn Company |
Method for the simultaneous detection of a therapeutic target for a disease state and its neutralizing antibody-like molecule
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
DK0970126T3
(da)
*
|
1997-04-14 |
2001-08-13 |
Micromet Ag |
Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
|
US20030148463A1
(en)
|
1997-04-14 |
2003-08-07 |
Micromet Ag |
Novel method for the production of anti-human antigen receptors and uses thereof
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
WO1999015897A1
(en)
*
|
1997-09-19 |
1999-04-01 |
Chiron Corporation |
Subtractive protein screening for gene identification
|
GB9722131D0
(en)
*
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
EP1965213A3
(de)
|
1998-02-04 |
2009-07-15 |
Invitrogen Corporation |
Microarrays und ihre Verwendungen
|
US6479256B1
(en)
|
1998-03-04 |
2002-11-12 |
Icos Corporation |
Lectomedin materials and methods
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
EP1093457B8
(de)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
EP1073671A4
(de)
*
|
1998-04-24 |
2004-08-18 |
Univ California |
Gezielter gentransport zu zellen durch filamentoesen bakteriophagen
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
US6794128B2
(en)
|
1998-04-24 |
2004-09-21 |
The Regents Of The University Of California |
Methods of selecting internalizing antibodies
|
GB9810040D0
(en)
|
1998-05-11 |
1998-07-08 |
Univ Nottingham |
Blood borne tumour markers
|
EP1078051B1
(de)
|
1998-05-13 |
2007-12-12 |
Domantis Limited |
Phagen-display-selektionssystem für korrekt gefaltete proteine
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
ES2331901T3
(es)
|
1998-06-12 |
2010-01-19 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
|
US6576478B1
(en)
*
|
1998-07-14 |
2003-06-10 |
Zyomyx, Inc. |
Microdevices for high-throughput screening of biomolecules
|
US20030138973A1
(en)
*
|
1998-07-14 |
2003-07-24 |
Peter Wagner |
Microdevices for screening biomolecules
|
US20020119579A1
(en)
*
|
1998-07-14 |
2002-08-29 |
Peter Wagner |
Arrays devices and methods of use thereof
|
US6406921B1
(en)
*
|
1998-07-14 |
2002-06-18 |
Zyomyx, Incorporated |
Protein arrays for high-throughput screening
|
US6780582B1
(en)
*
|
1998-07-14 |
2004-08-24 |
Zyomyx, Inc. |
Arrays of protein-capture agents and methods of use thereof
|
GB9827228D0
(en)
*
|
1998-12-10 |
1999-02-03 |
Univ Nottingham |
Cancer detection method and reagents
|
JP5550799B2
(ja)
|
1999-01-15 |
2014-07-16 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Tweakのアンタゴニストおよびtweakレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
|
AU2750800A
(en)
|
1999-02-01 |
2000-08-18 |
Amgen Canada Inc. |
Materials and methods to inhibit hodgkin and reed sternberg cell growth
|
US6303321B1
(en)
|
1999-02-11 |
2001-10-16 |
North Shore-Long Island Jewish Research Institute |
Methods for diagnosing sepsis
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US6890726B1
(en)
|
1999-04-06 |
2005-05-10 |
Oklahoma Medical Research Foundation |
Method for selecting recombinase variants with altered specificity
|
US6492497B1
(en)
*
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
AU782994C
(en)
*
|
1999-05-14 |
2006-08-24 |
Imclone Llc |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
CA2382587A1
(en)
|
1999-08-23 |
2001-03-01 |
Chugai Seiyaku Kabushiki Kaisha |
Hm1.24 antigen expression potentiators
|
US7084256B2
(en)
*
|
1999-09-24 |
2006-08-01 |
Large Scale Biology Corporation |
Self antigen vaccines for treating B cell lymphomas and other cancers
|
US20030039659A1
(en)
*
|
1999-09-24 |
2003-02-27 |
Mccormick Alison A. |
Self antigen vaccines for treating B cell lymphomas and other cancers
|
WO2001023619A1
(en)
|
1999-09-29 |
2001-04-05 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
US7037706B1
(en)
|
1999-09-29 |
2006-05-02 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
US6344549B1
(en)
|
1999-10-14 |
2002-02-05 |
Icos Corporation |
ATR-2 cell cycle checkpoint
|
CA2388599A1
(en)
|
1999-10-22 |
2001-05-03 |
Pharmacia & Upjohn Company |
Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
US6498026B2
(en)
|
2000-02-25 |
2002-12-24 |
Hercules Incorporated |
Variant galactose oxidase, nucleic acid encoding same, and methods of using same
|
EP1274720A4
(de)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
Albumin enthaltende fusionsproteine
|
ES2393535T3
(es)
*
|
2000-04-17 |
2012-12-26 |
Dyax Corp. |
Nuevos métodos para construir bibliotecas de paquetes genéticos que presentan de forma colectiva los miembros de una familia diversa de péptidos, polipéptidos o proteínas
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
CN1654956A
(zh)
*
|
2000-05-04 |
2005-08-17 |
耶鲁大学 |
用于筛选蛋白活性的高密度蛋白阵列
|
US6734005B2
(en)
|
2000-05-22 |
2004-05-11 |
Pharmacia & Upjohn Company |
Matrix metalloproteinases
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
US20030232399A1
(en)
*
|
2000-06-14 |
2003-12-18 |
Robertson John Forsyth Russell |
Cancer detection methods and reagents
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
UY26807A1
(es)
|
2000-06-29 |
2002-01-31 |
Abbott Lab |
Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos
|
AU2001271839A1
(en)
|
2000-07-05 |
2002-01-14 |
Pharmacia And Upjohn Company |
Human ion channels
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
AU9500201A
(en)
*
|
2000-08-09 |
2002-02-18 |
Imclone Systems Inc |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
GB0025144D0
(en)
*
|
2000-10-13 |
2000-11-29 |
Medical Res Council |
Concatenated nucleic acid sequences
|
US20030026806A1
(en)
*
|
2000-10-27 |
2003-02-06 |
Amgen Inc. |
Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
CA2429544C
(en)
*
|
2000-11-17 |
2010-10-19 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
EP2338512A1
(de)
|
2000-11-28 |
2011-06-29 |
MedImmune, LLC |
Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
AU2002249854B2
(en)
|
2000-12-18 |
2007-09-20 |
Dyax Corp. |
Focused libraries of genetic packages
|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Rgmおよびそのモジュレーターの用途
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2002338446A1
(en)
*
|
2001-01-23 |
2002-11-05 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
WO2002062850A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
CA2342376C
(en)
*
|
2001-03-20 |
2013-11-12 |
Marco Colonna |
A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
EP1385984A4
(de)
|
2001-03-21 |
2007-06-13 |
Xenoport Inc |
Auf einem icosaedrischen phagen präsentierte verbindung und verfahren zu deren verwendung
|
WO2002079429A2
(en)
*
|
2001-03-30 |
2002-10-10 |
The Regents Of The University Of California |
Anti-muc-1 single chain antibodies for tumor targeting
|
US7183388B2
(en)
*
|
2001-03-30 |
2007-02-27 |
The Regents Of The University Of California |
Anti-MUC-1 single chain antibodies for tumor targeting
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US7304034B2
(en)
*
|
2001-05-15 |
2007-12-04 |
The Feinstein Institute For Medical Research |
Use of HMGB fragments as anti-inflammatory agents
|
CN100594935C
(zh)
|
2001-05-25 |
2010-03-24 |
人体基因组科学有限公司 |
免疫特异性结合trail受体的抗体
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US6989452B2
(en)
*
|
2001-05-31 |
2006-01-24 |
Medarex, Inc. |
Disulfide prodrugs and linkers and stabilizers useful therefor
|
WO2004003019A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Domantis Limited |
Immunoglobin single variant antigen-binding domains and dual-specific constructs
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
TWI327597B
(en)
|
2001-08-01 |
2010-07-21 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US20040005709A1
(en)
*
|
2001-10-24 |
2004-01-08 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
Hybridization control of sequence variation
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
AU2002359568B2
(en)
|
2001-12-03 |
2008-02-21 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
EP2075256A2
(de)
|
2002-01-14 |
2009-07-01 |
William Herman |
Gezielte Liganden
|
AU2003214842A1
(en)
*
|
2002-01-17 |
2003-09-02 |
Albert Einstein College Of Medicine Of Yeshiva University |
Mutations caused by activation-induced cytidine deaminase
|
US20060046249A1
(en)
*
|
2002-01-18 |
2006-03-02 |
Fei Huang |
Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
|
DK1475101T3
(da)
|
2002-02-14 |
2011-01-10 |
Chugai Pharmaceutical Co Ltd |
Antistof-holdige farmaceutiske opløsninger
|
SI2336184T1
(sl)
|
2002-02-25 |
2015-04-30 |
Biogen Idec Ma Inc. |
Dajanje sredstev za zdravljenje vnetij
|
JP2005526506A
(ja)
|
2002-03-04 |
2005-09-08 |
イムクローン システムズ インコーポレイティド |
Kdrに特異的なヒト抗体及びその利用
|
US20030216551A1
(en)
*
|
2002-03-08 |
2003-11-20 |
Diabetogen Biosciences Inc. |
Fully human anti-CD3 monoclonal antibodies
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
US20030186221A1
(en)
*
|
2002-04-02 |
2003-10-02 |
Lockhart David J. |
Phage display affinity filter and forward screen
|
US7112435B1
(en)
|
2002-08-07 |
2006-09-26 |
Ambit Biosciences Corporation |
Uncoupling of DNA insert propagation and expression of protein for phage display
|
DK1997512T3
(da)
|
2002-04-09 |
2014-01-27 |
Biogen Idec Inc |
Fremgangsmåder til behandling af TWEAK-relaterede tilstande
|
EP1499352A4
(de)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Rekombinante anti-interleukin-9-antikörper
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
AU2003274463B2
(en)
*
|
2002-06-10 |
2009-10-29 |
University Of Rochester |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
CA2491471A1
(en)
*
|
2002-07-03 |
2004-01-15 |
The Trustees Of The University Of Pennsylvania |
Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
|
AU2003247869C1
(en)
|
2002-07-15 |
2009-12-24 |
Board Of Regents, The University Of Texas System |
Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
AU2003257109A1
(en)
*
|
2002-08-05 |
2004-02-23 |
Invitrogen Corporation |
Compositions and methods for molecular biology
|
US7833741B2
(en)
*
|
2002-08-07 |
2010-11-16 |
Ambit Biosciences Corporation |
Uncoupling of DNA insert propagation and expression of protein for phage display
|
US7897381B2
(en)
*
|
2002-08-07 |
2011-03-01 |
Ambit Biosciences Corporation |
Uncoupling of DNA insert propagation and expression of protein for phage display
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
JP4459810B2
(ja)
|
2002-08-14 |
2010-04-28 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体とその利用法
|
US20050233473A1
(en)
*
|
2002-08-16 |
2005-10-20 |
Zyomyx, Inc. |
Methods and reagents for surface functionalization
|
WO2004019966A1
(ja)
|
2002-08-27 |
2004-03-11 |
Chugai Seiyaku Kabushiki Kaisha |
タンパク質溶液製剤の安定化方法
|
KR101119448B1
(ko)
|
2002-09-11 |
2012-03-15 |
추가이 세이야쿠 가부시키가이샤 |
단백질 정제 방법
|
DE60336406D1
(de)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
GB2424273B
(en)
|
2002-11-14 |
2007-06-27 |
Univ Nottingham |
Method for preparing tumour marker protein
|
CN100434440C
(zh)
*
|
2002-12-02 |
2008-11-19 |
阿布格尼克斯公司 |
针对肿瘤坏死因子的抗体及其用途
|
US6974860B2
(en)
*
|
2002-12-30 |
2005-12-13 |
Kimberly-Clark Worldwide, Inc. |
Target recognizing binding agents
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
JP2006518997A
(ja)
*
|
2003-01-21 |
2006-08-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規アシルコエンザイムa:モノアシルグリセロールアシルトランスフェラーゼ−3(mgat3)をコードするポリヌクレオチドおよびその用途
|
CA2514125A1
(en)
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2515779A1
(en)
|
2003-02-14 |
2004-09-02 |
The Curators Of The University Of Missouri |
Contraceptive method and compositions related to proteasomal interference
|
ES2457538T3
(es)
|
2003-02-20 |
2014-04-28 |
Seattle Genetics, Inc. |
Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
|
PT2248899E
(pt)
|
2003-03-19 |
2015-09-23 |
Biogen Ma Inc |
Proteína de ligação do receptor nogo
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
CA2524305C
(en)
|
2003-05-01 |
2015-12-08 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
US20090005257A1
(en)
|
2003-05-14 |
2009-01-01 |
Jespers Laurent S |
Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
|
US8088387B2
(en)
*
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
SI3524611T1
(sl)
|
2003-05-20 |
2021-05-31 |
Immunogen, Inc. |
Izboljšana citotoksična sredstva, ki vsebujejo nove majtanzinoide
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
WO2004106380A2
(en)
*
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Human-anti-human cd3 binding molecules
|
US20040248323A1
(en)
*
|
2003-06-09 |
2004-12-09 |
Protometrix, Inc. |
Methods for conducting assays for enzyme activity on protein microarrays
|
DE602004028249D1
(de)
|
2003-06-18 |
2010-09-02 |
Chugai Pharmaceutical Co Ltd |
Fucosetransporter
|
AU2004250256B8
(en)
*
|
2003-06-20 |
2010-04-08 |
Ambit Biosciences Corporation |
Assay and kits for detecting protein binding
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
MEP31408A
(en)
|
2003-07-18 |
2010-10-10 |
Abgenix Inc |
Specific binding agents to hepatocyte growth factor
|
CA2445420A1
(en)
*
|
2003-07-29 |
2005-01-29 |
Invitrogen Corporation |
Kinase and phosphatase assays
|
US7727752B2
(en)
*
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
US7619059B2
(en)
*
|
2003-07-29 |
2009-11-17 |
Life Technologies Corporation |
Bimolecular optical probes
|
EP1652923B1
(de)
|
2003-08-08 |
2011-10-12 |
Perseus Proteomics Inc. |
Bei krebs überexprimiertes gen
|
JP2007511738A
(ja)
|
2003-08-08 |
2007-05-10 |
ジーンニュース インコーポレーテッド |
変形性関節症のバイオマーカー及びその使用
|
ES2458636T3
(es)
|
2003-08-18 |
2014-05-06 |
Medimmune, Llc |
Humanización de anticuerpos
|
US20120202710A1
(en)
*
|
2003-09-09 |
2012-08-09 |
Integrigen, Inc. |
Methods and compositions for generation of germline human antibody genes
|
US7046714B2
(en)
*
|
2003-09-10 |
2006-05-16 |
Intel Corporation |
Method and apparatus for Raman ring resonator based laser/wavelength converter
|
CA2538763C
(en)
*
|
2003-09-11 |
2015-05-05 |
Critical Therapeutics, Inc. |
Monoclonal antibodies against hmgb1
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
CN1882602B
(zh)
|
2003-10-10 |
2011-02-09 |
阿尔卡米亚肿瘤股份有限公司 |
在疾病治疗中乙酰透明质酸合成的调节和降解
|
US20070269428A1
(en)
|
2003-11-21 |
2007-11-22 |
Celltech R&D Limited |
Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
|
AU2004296184B2
(en)
*
|
2003-12-04 |
2010-12-16 |
Vaccinex, Inc. |
Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
|
PT1691837E
(pt)
|
2003-12-10 |
2012-08-27 |
Medarex Inc |
Anticorpos ip-10 e suas utilizações
|
EP2418220B1
(de)
|
2003-12-10 |
2017-08-02 |
E. R. Squibb & Sons, L.L.C. |
Interferon-Alpha-Antikörper und deren Verwendungen
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
DK1711528T3
(da)
|
2003-12-23 |
2012-08-20 |
Genentech Inc |
Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
|
AU2005207003C1
(en)
|
2004-01-20 |
2013-06-13 |
Humanigen, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
BRPI0507026A
(pt)
|
2004-02-09 |
2007-04-17 |
Human Genome Sciences Inc |
proteìnas de fusão de albumina
|
DE602005018325D1
(de)
|
2004-02-19 |
2010-01-28 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
US20060024302A1
(en)
|
2004-03-05 |
2006-02-02 |
Ludwig Institute For Cancer Research |
Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
|
JP4734319B2
(ja)
|
2004-03-19 |
2011-07-27 |
イムクローン・リミテッド・ライアビリティ・カンパニー |
ヒト抗上皮成長因子受容体抗体
|
WO2005097184A2
(en)
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
EP1745149A4
(de)
|
2004-04-15 |
2008-08-06 |
Univ Florida |
Neurale proteine als biomarker für eine verletzung des nervensystems und andere neurale störungen
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
RU2402548C2
(ru)
*
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
AU2005244980B2
(en)
*
|
2004-05-19 |
2011-09-15 |
E. R. Squibb & Sons, L.L.C. |
Chemical linkers and conjugates thereof
|
EA012622B1
(ru)
|
2004-06-01 |
2009-10-30 |
Домэнтис Лимитед |
Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
|
WO2005118635A2
(en)
*
|
2004-06-03 |
2005-12-15 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
KR20150041193A
(ko)
|
2004-06-21 |
2015-04-15 |
메다렉스, 엘.엘.시. |
인터페론 알파 수용체 1 항체 및 그의 용도
|
PT1776136E
(pt)
|
2004-06-24 |
2012-12-05 |
Biogen Idec Inc |
Tratamento de estados que envolvem desmielinização
|
PL1781321T3
(pl)
|
2004-08-02 |
2014-07-31 |
Zenyth Operations Pty Ltd |
Sposób leczenia raka zawierający antagonistę VEGF-B
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
AU2005286770A1
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
WO2006050257A2
(en)
*
|
2004-10-29 |
2006-05-11 |
Massachusetts Institute Of Tecchnology |
Detection of ion channel or receptor activity
|
EP2377555A3
(de)
|
2004-11-18 |
2011-11-23 |
Imclone LLC |
Antikörper gegen den vaskulären endothelialen Wachstumsfaktorrezeptor-1
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
EP1841796A2
(de)
|
2004-12-02 |
2007-10-10 |
Domantis Limited |
Bispezifische domänen-antikörper gegen serum albumin und glp-1 oder pyy
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
AU2005313026B2
(en)
|
2004-12-06 |
2011-09-08 |
Kyowa Hakko Kirin Co., Ltd. |
Human monoclonal antibodies to influenza M2 protein and methods of making and using same
|
US20080003617A1
(en)
*
|
2004-12-20 |
2008-01-03 |
Xiaomin Fan |
Methods for the identification and the isolation of epitope specific antibodies
|
US20060134698A1
(en)
*
|
2004-12-20 |
2006-06-22 |
Evanston Northwestern Healthcare Research Institute |
Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
PL1835922T3
(pl)
*
|
2004-12-22 |
2009-10-30 |
Merck Serono Sa |
Terapia skojarzona stwardnienia rozsianego
|
EP2520669A3
(de)
|
2005-02-07 |
2013-02-27 |
GeneNews Inc. |
Biomarker für milde Arthrose und Verwendungen davon
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
EP1853322B1
(de)
|
2005-02-11 |
2014-06-25 |
ImmunoGen, Inc. |
Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
|
US7811572B2
(en)
|
2005-08-24 |
2010-10-12 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
CA2597945C
(en)
|
2005-02-17 |
2016-07-12 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
EP1851250B1
(de)
*
|
2005-02-18 |
2012-06-06 |
Medarex, Inc. |
Menschlicher monoklonaler antikörper gegen ein prostataspezifisches membranantigen
|
US8211430B2
(en)
|
2005-03-04 |
2012-07-03 |
Curedm Group Holdings, Llc |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
EP3050963B1
(de)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
EP1868650B1
(de)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Kovalente diabodies und ihre verwendung
|
EP1871418B1
(de)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
KR101498834B1
(ko)
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
CA2607697C
(en)
|
2005-05-10 |
2015-01-06 |
Biogen Idec Ma Inc. |
Treating and evaluating inflammatory disorders
|
CA2726759C
(en)
|
2005-05-25 |
2016-02-16 |
Curedm Group Holdings, Llc |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
DK1888113T3
(da)
|
2005-05-27 |
2014-09-01 |
Biogen Idec Inc |
Tweak-bindende antistoffer
|
GB2426581A
(en)
|
2005-05-27 |
2006-11-29 |
Univ Nottingham |
Immunoassay methods
|
RU2636532C2
(ru)
|
2005-05-27 |
2017-11-23 |
Онкиммьюн Лимитед |
Улучшенные способы иммуноанализа
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
PT2163562E
(pt)
|
2005-06-21 |
2013-12-19 |
Xoma Us Llc |
Anticorpos de ligação a il 1 beta e respectivos fragmentos
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
PT1896073E
(pt)
|
2005-06-30 |
2013-05-28 |
Janssen Biotech Inc |
Composições, métodos e aplicações de anticorpos anti-il-23
|
CN103172739A
(zh)
|
2005-06-30 |
2013-06-26 |
Abbvie公司 |
Il-12/p40结合蛋白
|
HUE026039T2
(en)
|
2005-07-01 |
2016-05-30 |
Squibb & Sons Llc |
Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
|
SI1904104T1
(sl)
|
2005-07-08 |
2013-12-31 |
Biogen Idec Ma Inc. |
Protitelesa SP35 in njihova uporaba
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
ES2539250T3
(es)
|
2005-07-25 |
2015-06-29 |
Emergent Product Development Seattle, Llc |
Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
|
EP1920057A4
(de)
|
2005-08-03 |
2009-03-18 |
Grains Res & Dev Corp |
Polysaccharid-synthasen
|
PT2573114T
(pt)
|
2005-08-10 |
2016-07-13 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
|
JP2009504685A
(ja)
*
|
2005-08-15 |
2009-02-05 |
アラーナ・テラピューティクス・リミテッド |
新世界霊長類フレームワーク領域を用いる設計された抗体
|
EP2500357A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
EA014025B1
(ru)
*
|
2005-09-12 |
2010-08-30 |
Новиммун С.А. |
Композиции антитела против cd3
|
EP1926757B1
(de)
|
2005-09-14 |
2012-02-22 |
UCB Pharma, S.A. |
Antikörper-kammpolymer-konjugat
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
CA2623652C
(en)
*
|
2005-09-26 |
2013-11-26 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
JP2009510002A
(ja)
*
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
BRPI0617378B8
(pt)
|
2005-10-14 |
2022-09-20 |
Chugai Pharmaceutical Co Ltd |
Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
|
CN102260742A
(zh)
|
2005-10-21 |
2011-11-30 |
基因信息股份有限公司 |
用于使生物标志产物水平与疾病相关联的方法和装置
|
PE20080036A1
(es)
|
2005-10-21 |
2008-03-06 |
Novartis Ag |
Anticuerpos humanos para la interleucina-13 (il13)
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
DK1940789T3
(da)
|
2005-10-26 |
2012-03-19 |
Medarex Inc |
Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger
|
US20070099246A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Sandy John D |
Antibodies, assays and kits to quantitate cartilage destruction
|
EP1959979A4
(de)
|
2005-11-04 |
2010-01-27 |
Biogen Idec Inc |
Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
|
EP3299027A1
(de)
|
2005-11-04 |
2018-03-28 |
Genentech, Inc. |
Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
|
AU2006311661B2
(en)
|
2005-11-07 |
2011-05-26 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
EP2465870A1
(de)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
US8128934B2
(en)
|
2005-11-14 |
2012-03-06 |
Ribomic, Inc. |
Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
TW200803894A
(en)
|
2005-11-25 |
2008-01-16 |
Univ Keio |
Prostate cancer therapeutic agents
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
US20070122413A1
(en)
|
2005-11-28 |
2007-05-31 |
Sivakumar Pallavur V |
Il-21 antagonists
|
RS53270B2
(sr)
|
2005-11-30 |
2018-05-31 |
Abbvie Deutschland |
Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
|
JP5475994B2
(ja)
|
2005-11-30 |
2014-04-16 |
アッヴィ・インコーポレイテッド |
抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
|
EP1965827B1
(de)
|
2005-12-02 |
2015-02-25 |
Biogen Idec MA Inc. |
Behandlung von entmyelinisierenden erkrankungen
|
RU2470941C2
(ru)
|
2005-12-02 |
2012-12-27 |
Дженентек, Инк. |
Связывающие полипептиды и их применения
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法
|
WO2007066082A1
(en)
|
2005-12-09 |
2007-06-14 |
Ucb Pharma S.A. |
Antibody molecules having specificity for human il-6
|
EP1803814A1
(de)
|
2005-12-27 |
2007-07-04 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Methode zur Verbesserung der Antikörperselektionskapazität in einer Phagen-Display-Bibliothek
|
EP1977763A4
(de)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Antikörper-enthaltende stabilisierende zubereitung
|
MX2008008621A
(es)
|
2005-12-29 |
2008-11-27 |
Centocor Inc |
Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
|
US20070160325A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Hyungbin Son |
Angle-tunable transmissive grating
|
US20070166774A1
(en)
*
|
2006-01-17 |
2007-07-19 |
Groman Ernest V |
Functional immunoassay
|
ES2550099T3
(es)
|
2006-01-27 |
2015-11-04 |
Biogen Ma Inc. |
Antagonistas del receptor Nogo
|
AU2007208678B2
(en)
|
2006-01-27 |
2013-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for diseases involving choroidal neovascularization
|
US20080038761A1
(en)
*
|
2006-01-30 |
2008-02-14 |
Invitrogen Corporation |
Compositions and methods for detecting and quantifying toxic substances in disease states
|
EP1987064A4
(de)
*
|
2006-02-01 |
2010-04-07 |
Arana Therapeutics Ltd |
Domänen-antikörper-konstrukt
|
EP2650306A1
(de)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
EP3345616A1
(de)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
|
JP5514539B2
(ja)
|
2006-03-31 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
|
IN2014DN10515A
(de)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
EP2025346B1
(de)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Mittel zur förderung der muskelregeneration
|
US20100080794A1
(en)
|
2006-04-14 |
2010-04-01 |
Takashi Tsuji |
Mutant polypeptide having effector function
|
WO2010123874A1
(en)
|
2009-04-20 |
2010-10-28 |
Oxford Biotherapeutics Ltd. |
Antibodies specific to cadherin-17
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
ES2429407T3
(es)
|
2006-06-08 |
2013-11-14 |
Chugai Seiyaku Kabushiki Kaisha |
Agente preventivo o remedio para enfermedades inflamatorias
|
SG172698A1
(en)
|
2006-06-12 |
2011-07-28 |
Trubion Pharmaceuticals Inc |
Single-chain multivalent binding proteins with effector function
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
WO2008019199A2
(en)
|
2006-06-26 |
2008-02-14 |
Macrogenics, Inc. |
FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
TW200808351A
(en)
|
2006-07-13 |
2008-02-16 |
Chugai Pharmaceutical Co Ltd |
Cell death-inducing agents
|
EA020324B1
(ru)
|
2006-07-18 |
2014-10-30 |
Санофи-Авентис |
АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
|
EP2047862B9
(de)
|
2006-07-21 |
2013-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Mittel zur behandlung von nierenerkrankungen
|
JP5235881B2
(ja)
*
|
2006-08-11 |
2013-07-10 |
シーエスエル、リミテッド |
肺疾患病態の処理
|
JP5244785B2
(ja)
|
2006-08-11 |
2013-07-24 |
小野薬品工業株式会社 |
ストローマ由来因子−1(sdf−1)に対するモノクローナル抗体
|
EP3111955B1
(de)
|
2006-08-14 |
2019-01-23 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnose und behandlung von krebs mittels anti-desmoglein-3 antikörper
|
JP5517619B2
(ja)
|
2006-08-18 |
2014-06-11 |
ノバルティス アーゲー |
Prlr特異的抗体およびその使用
|
SG170032A1
(en)
|
2006-08-28 |
2011-04-29 |
Kyowa Hakko Kirin Co Ltd |
Antagonistic human light-specific human monoclonal antibodies
|
MX2009002418A
(es)
|
2006-09-05 |
2009-04-23 |
Medarex Inc |
Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
|
SG174782A1
(en)
|
2006-09-08 |
2011-10-28 |
Abbott Lab |
Interleukin - 13 binding proteins
|
CN101632020B
(zh)
|
2006-09-13 |
2013-11-27 |
昂西免疫有限公司 |
改进的免疫测定方法
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
US20090252745A1
(en)
*
|
2006-09-15 |
2009-10-08 |
Duke University |
Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
|
EP2066693A2
(de)
|
2006-09-22 |
2009-06-10 |
St. Jude Children's Research Hospital |
Modulation der regulatorischen aktivität von t-zellen mittels interleukin-35
|
PT2486941T
(pt)
|
2006-10-02 |
2017-05-30 |
Squibb & Sons Llc |
Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
CN103396486A
(zh)
|
2006-10-12 |
2013-11-20 |
中外制药株式会社 |
使用抗ereg抗体的癌症的诊断和治疗
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
PL2829551T3
(pl)
|
2006-10-19 |
2018-04-30 |
Csl Limited |
Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
|
DK2068922T3
(da)
|
2006-10-19 |
2012-10-08 |
Csl Ltd |
Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
US9023993B2
(en)
|
2006-10-20 |
2015-05-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
EP3040347A3
(de)
|
2006-10-20 |
2016-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmazeutische zusammensetzung mit anti-hb-egf-antikörper als wirkstoff
|
EP2087007A2
(de)
|
2006-11-09 |
2009-08-12 |
Irm Llc |
Agonistische trkb-antikörper und ihre verwendung
|
NZ577085A
(en)
|
2006-11-15 |
2012-06-29 |
Medarex Inc |
Human monoclonal antibodies to btla and methods of use
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
CA2683287A1
(en)
|
2006-11-27 |
2008-12-18 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
US8067179B2
(en)
*
|
2006-11-30 |
2011-11-29 |
Research Development Foundation |
Immunoglobulin libraries
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
CN103172743B
(zh)
|
2006-12-01 |
2015-04-08 |
梅达雷克斯有限责任公司 |
结合cd22的人抗体及其用途
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
KR101519672B1
(ko)
|
2006-12-07 |
2015-05-29 |
노파르티스 아게 |
Ephb3에 대한 길항제 항체
|
US20080139790A1
(en)
*
|
2006-12-08 |
2008-06-12 |
Jennings Philip A |
Chimeric antibodies
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
EP2103628A4
(de)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
|
RU2554747C9
(ru)
*
|
2006-12-20 |
2015-10-20 |
Ксома (Сша) Ллс |
Способы лечения il-1бета-зависимых заболеваний
|
US9127064B2
(en)
|
2006-12-21 |
2015-09-08 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
US8324350B2
(en)
*
|
2006-12-29 |
2012-12-04 |
Abbott Laboratories |
Dual-specific IL-1α/IL-1β antibodies
|
JP5618172B2
(ja)
|
2007-01-05 |
2014-11-05 |
国立大学法人東京大学 |
抗prg−3抗体を用いる癌の診断および治療
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
NZ577976A
(en)
|
2007-01-09 |
2011-12-22 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof
|
WO2008088823A2
(en)
|
2007-01-16 |
2008-07-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
CL2008000188A1
(es)
|
2007-01-23 |
2008-07-18 |
Chugai Pharmaceutical Co Ltd |
Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
PT2129396E
(pt)
|
2007-02-16 |
2013-11-18 |
Merrimack Pharmaceuticals Inc |
Anticorpos contra erbb3 e suas utilizações
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
US8114606B2
(en)
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
JP2010520748A
(ja)
|
2007-02-20 |
2010-06-17 |
アナプティスバイオ インコーポレイティッド |
体細胞超変異系
|
KR20090122439A
(ko)
|
2007-02-21 |
2009-11-30 |
메다렉스, 인코포레이티드 |
단일 아미노산을 갖는 화학적 링커 및 이의 접합체
|
EP2121745A2
(de)
|
2007-02-26 |
2009-11-25 |
Oxford Genome Sciences (UK) Limited |
Proteine
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
WO2008105560A1
(ja)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
抗grp78抗体を有効成分として含む医薬組成物
|
EP2124952A2
(de)
*
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Verfahren zur behandlung von amyloidosen
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
BRPI0809042B1
(pt)
|
2007-03-22 |
2021-08-31 |
Biogen Ma Inc. |
Proteína de ligação a cd154 isolada, seu uso, e composição
|
WO2008121615A2
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Inc. |
Antibody formulation
|
BRPI0809989B8
(pt)
|
2007-04-02 |
2021-05-25 |
Philogen Spa |
usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina
|
MX2009011226A
(es)
|
2007-04-17 |
2010-04-01 |
Imclone Llc |
Inhibidores especificos pdgfrbeta.
|
WO2008137475A2
(en)
*
|
2007-05-01 |
2008-11-13 |
Research Development Foundation |
Immunoglobulin fc libraries
|
PT2164868E
(pt)
|
2007-05-04 |
2015-08-04 |
Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa |
Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
AU2008255027B2
(en)
|
2007-05-14 |
2013-10-03 |
Astrazeneca Ab |
Methods of reducing eosinophil levels
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
CA2688434A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
GB0724331D0
(en)
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
KR101799337B1
(ko)
|
2007-06-21 |
2017-12-20 |
마크로제닉스, 인크. |
공유결합형 디아바디 및 이것의 사용
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
C末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
JP2010534828A
(ja)
*
|
2007-07-23 |
2010-11-11 |
ビオエクセル エスピーエー |
スクリーニング、療法及び診断
|
WO2009015063A2
(en)
|
2007-07-23 |
2009-01-29 |
Centocor |
Methods and compositions for treating fibrosis related disorders using il-17 antagonists
|
CA2691218C
(en)
|
2007-07-25 |
2018-04-24 |
Philogen S.P.A. |
An antigen associated with lung cancers and lymphomas
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
WO2009054873A2
(en)
|
2007-08-02 |
2009-04-30 |
Novimmune S.A. |
Anti-rantes antibodies and methods of use thereof
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP4248976A3
(de)
|
2007-08-23 |
2024-04-10 |
Amgen Inc. |
Antigen zur bindung von proteinen an proprotein-konvertase-subtilisin/kexin vom typ 9 (pcsk9)
|
RU2015147300A
(ru)
|
2007-08-29 |
2019-01-11 |
Санофи-Авентис |
Гуманизированные антитела к cxcr5, их производные и их применение
|
SG185940A1
(en)
|
2007-08-30 |
2012-12-28 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
NZ583966A
(en)
|
2007-08-30 |
2012-04-27 |
Daiichi Sankyo Co Ltd |
Anti-epha2 antibody
|
EP2190469B1
(de)
|
2007-09-04 |
2015-02-25 |
Compugen Ltd. |
Polypeptide und polynukleotide und ihre verwendung als zielmolekül zur herstellung von arzneimitteln und biologika
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
US8877688B2
(en)
*
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
DK3124497T3
(da)
|
2007-09-14 |
2020-05-11 |
Adimab Llc |
Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf
|
CA2700714C
(en)
|
2007-09-26 |
2018-09-11 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
CA2700701C
(en)
|
2007-09-26 |
2020-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
EP2584043A3
(de)
|
2007-09-28 |
2013-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-Glypican-3-Antikörper mit verbesserter Kinetik in Plasma
|
BR122019021238B8
(pt)
|
2007-10-02 |
2021-07-27 |
Chugai Pharmaceutical Co Ltd |
uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
|
EP2206727B1
(de)
|
2007-10-11 |
2015-04-01 |
Daiichi Sankyo Company, Limited |
AUF DAS OSTEOCLAST-RELATED PROTEIN Siglec-15 ZIELENDER ANTIKÖRPER
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
ES2499391T5
(es)
|
2007-10-15 |
2021-12-22 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de anticuerpos
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
EA201000603A1
(ru)
|
2007-10-23 |
2010-12-30 |
Новартис Аг |
ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
|
EP2230300A4
(de)
|
2007-10-24 |
2012-08-08 |
Otsuka Chemical Holdings Co Ltd |
Polypeptid mit verbesserter effektorfunktion
|
SI2209805T1
(sl)
|
2007-10-30 |
2017-11-30 |
Philogen S.P.A. |
Antigen, povezan z revmatoidnim artritisom
|
ES2560532T3
(es)
|
2007-11-02 |
2016-02-19 |
Novartis Ag |
Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
|
CA2703705A1
(en)
|
2007-11-05 |
2009-05-14 |
Medimmune, Llc |
Methods of treating scleroderma
|
ES2445755T3
(es)
|
2007-11-07 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
|
WO2009063970A1
(ja)
|
2007-11-14 |
2009-05-22 |
Forerunner Pharma Research Co., Ltd. |
抗gpr49抗体を用いる癌の診断および治療
|
SG188134A1
(en)
|
2007-11-15 |
2013-03-28 |
Chugai Pharmaceutical Co Ltd |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
HUE033825T2
(en)
|
2007-11-16 |
2018-01-29 |
Univ Rockefeller |
Beta-amyloid protein protofibrillum-specific antibodies
|
EP3115469B1
(de)
|
2007-11-19 |
2020-04-29 |
Celera Corporation |
Lungenkrebsmarker und verwendungen davon
|
AR069393A1
(es)
|
2007-11-21 |
2010-01-20 |
Imclone Systems Inc |
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
|
AU2008329466B2
(en)
|
2007-11-27 |
2015-04-09 |
The University Of British Columbia |
14-3-3 antagonists for the prevention and treatment of arthritis
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
UY31504A1
(es)
|
2007-11-30 |
2009-07-17 |
|
Construcciones de union de antigenos
|
WO2009072598A1
(ja)
|
2007-12-05 |
2009-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
掻痒症治療剤
|
ES2834741T3
(es)
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-NR10 y uso del mismo
|
EP2241333A1
(de)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutisches mittel gegen mll-leukämie und moz-leukämie, dessen ziel der m-csf-rezeptor ist, und seine anwendung
|
EP2594590B1
(de)
|
2007-12-14 |
2014-11-12 |
Bristol-Myers Squibb Company |
Verfahren zur Herstellung von Bindungsmolekülen für den humanen OX40-Rezeptor
|
AU2008343085B2
(en)
*
|
2007-12-20 |
2015-03-12 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
MX343594B
(es)
|
2007-12-21 |
2016-11-11 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
EP2235058A2
(de)
|
2007-12-21 |
2010-10-06 |
Amgen, Inc |
Anti-amyloid-antikörper und ihre verwendung
|
GB0725239D0
(en)
*
|
2007-12-24 |
2008-02-06 |
Oncimmune Ltd |
Calibrator for autoantibody assay
|
WO2009082485A1
(en)
|
2007-12-26 |
2009-07-02 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
AU2009203350B2
(en)
|
2008-01-11 |
2014-03-13 |
Gene Techno Science Co., Ltd. |
Humanized anti-alpha9 integrin antibodies and the uses thereof
|
WO2009087978A1
(ja)
|
2008-01-11 |
2009-07-16 |
The University Of Tokyo |
抗cldn6抗体
|
CA2711736A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
ES2500066T3
(es)
|
2008-01-25 |
2014-09-30 |
Amgen, Inc |
Anticuerpos frente a ferroportina y métodos de uso
|
CN104250301A
(zh)
|
2008-01-31 |
2014-12-31 |
美国政府健康及人类服务部 |
工程化抗体恒定结构域分子
|
EP2240203B1
(de)
|
2008-02-05 |
2014-04-09 |
Bristol-Myers Squibb Company |
Alpha-5-beta-1-antikörper und ihre verwendungen
|
EP2250279B1
(de)
|
2008-02-08 |
2016-04-13 |
MedImmune, LLC |
Anti-ifnar1-antikörper mit reduzierter fc-ligandenaffinität
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US7951370B2
(en)
|
2008-03-12 |
2011-05-31 |
Imclone Llc |
Anti-TYRP1 antibodies
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
BR122012027456A2
(pt)
|
2008-03-14 |
2015-07-14 |
Allergan Inc |
Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a
|
TW201513883A
(zh)
|
2008-03-18 |
2015-04-16 |
Abbvie Inc |
治療牛皮癬的方法
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
MX348362B
(es)
|
2008-03-31 |
2017-06-07 |
Genentech Inc * |
Composiciones y metodos para tratar y diagnosticar asma.
|
EP3045475B1
(de)
|
2008-04-02 |
2017-10-04 |
MacroGenics, Inc. |
Bcr-komplex-spezifische antikorper und verfahren zu ihrer verwendung
|
DK2247304T3
(en)
|
2008-04-02 |
2016-09-26 |
Macrogenics Inc |
Her2 / neu-specific antibodies and methods of use thereof
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
NZ603059A
(en)
*
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
MY159553A
(en)
|
2008-04-11 |
2017-01-13 |
Seattle Genetics Inc |
Detection and treatment of pancreatic, ovarian and other cancers
|
SG189775A1
(en)
|
2008-04-11 |
2013-05-31 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
JP5780951B2
(ja)
|
2008-04-24 |
2015-09-16 |
ダイアックス コーポレーション |
新規のhccdr1、cdr2、およびcdr3設計、ならびに新規のlccdr1、cdr2、およびcdr3設計を含む、遺伝子パッケージのライブラリ
|
AU2009238897B2
(en)
|
2008-04-24 |
2015-03-19 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
DK2281006T3
(da)
|
2008-04-30 |
2017-11-06 |
Immunogen Inc |
Tværbindingsmidler og anvendelser deraf
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
ES2458541T3
(es)
|
2008-05-02 |
2014-05-06 |
Seattle Genetics, Inc. |
Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
|
CN102089430B
(zh)
|
2008-05-09 |
2015-02-04 |
Abbvie公司 |
针对渐进性糖化终极产物受体(rage)的抗体及其用途
|
EP2599793A1
(de)
|
2008-05-29 |
2013-06-05 |
Nuclea Biotechnologies, Inc. |
Anti-Phosphor-AKT-Antikörper
|
AR071891A1
(es)
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
EP3002299A1
(de)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
ES2675730T3
(es)
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
TW201503898A
(zh)
|
2008-06-05 |
2015-02-01 |
Chugai Pharmaceutical Co Ltd |
神經浸潤抑制劑
|
US20110189172A1
(en)
*
|
2008-06-06 |
2011-08-04 |
Xoma Technology, Ltd. |
Methods for the treatment of rheumatoid arthritis
|
NZ589795A
(en)
|
2008-06-16 |
2013-02-22 |
Patrys Ltd |
Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
|
KR20110038047A
(ko)
|
2008-06-20 |
2011-04-13 |
고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 |
산화 LDL/β2GPI복합체에 대한 항체 및 그 용도
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
MX2011000236A
(es)
|
2008-07-08 |
2011-02-24 |
Oncomed Pharm Inc |
Agentes de union a notch y antagonistas y metodos de uso de los mismos.
|
EP2310049A4
(de)
|
2008-07-08 |
2013-06-26 |
Abbvie Inc |
Prostaglandin-e2 bindende proteine und ihre verwendung
|
EP2315779A2
(de)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
|
WO2010010469A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Abbott Gmbh & Co. Kg |
Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
|
EP2316030B1
(de)
|
2008-07-25 |
2019-08-21 |
Wagner, Richard W. |
Proteinscreeningverfahren
|
EP2815766B1
(de)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
AU2009289545A1
(en)
|
2008-09-05 |
2010-03-11 |
Xoma (Us) Llc |
Methods for improvement of beta cell function
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
US20120251502A1
(en)
|
2008-10-24 |
2012-10-04 |
The Government of the US as Represented by the Secretary of the Dept. of health |
Human Ebola Virus Species and Compositions and Methods Thereof
|
DK2356269T3
(en)
|
2008-10-31 |
2016-08-15 |
Janssen Biotech Inc |
FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
|
WO2010054007A1
(en)
|
2008-11-07 |
2010-05-14 |
Fabrus Llc |
Combinatorial antibody libraries and uses thereof
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
EP2358392B1
(de)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antikörper-formulierung
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
EP2364326B1
(de)
|
2008-12-05 |
2018-07-04 |
Glaxo Group Limited |
Verfahren zur selektion proteaseresistenter polypeptide
|
CN102300874B
(zh)
|
2008-12-08 |
2015-08-05 |
卡姆普根有限公司 |
Tmem154多肽和多核苷酸及其作为产生药物和生物制品的药物靶标的用途
|
EA201100943A1
(ru)
|
2008-12-16 |
2012-05-30 |
Новартис Аг |
Системы дрожжевого дисплея
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
MX2011006908A
(es)
|
2008-12-26 |
2011-10-06 |
Univ Tokio |
Diagnosis y tratamiento del cancer utilizando el anticuerpo anti-lgr7.
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010078950A2
(en)
|
2009-01-07 |
2010-07-15 |
Philogen S.P.A. |
Antigens associated with endometriosis, psoriatic arthritis and psoriasis
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
CA2749572A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
EP2389195B1
(de)
|
2009-01-20 |
2015-05-20 |
Homayoun H. Zadeh |
Antikörpervermittelte knochenregeneration
|
US20120058131A1
(en)
|
2009-01-21 |
2012-03-08 |
Oxford Biotherapeutics Ltd |
Pta089 protein
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
MX368362B
(es)
|
2009-02-05 |
2019-09-30 |
Immunogen Inc |
Derivados novedosos de benzodiacepina.
|
US20120165340A1
(en)
|
2009-02-11 |
2012-06-28 |
Ludwing Institute For Cancer Research Ltd. |
Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
|
CA2752211C
(en)
|
2009-02-12 |
2020-03-24 |
Janssen Biotech, Inc. |
Fibronectin type iii domain based scaffold compositions, methods and uses
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
PL2398498T3
(pl)
|
2009-02-17 |
2019-03-29 |
Ucb Biopharma Sprl |
Cząsteczki przeciwciał swoiste wobec ludzkiego OX40
|
EP2401298A1
(de)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigenbindende konstrukte
|
WO2010097394A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Multivalent and/or multispecific rankl-binding constructs
|
WO2010097386A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
US8420084B2
(en)
|
2009-03-05 |
2013-04-16 |
Medarex, Inc. |
Fully human antibodies specific to CADM1
|
RU2015132478A
(ru)
|
2009-03-05 |
2015-12-10 |
Эббви Инк. |
Связывающие il-17 белки
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
WO2010104208A1
(en)
|
2009-03-10 |
2010-09-16 |
Gene Techno Science Co., Ltd. |
Generation, expression and characterization of the humanized k33n monoclonal antibody
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
CA2753894C
(en)
|
2009-03-13 |
2017-12-05 |
Allergan, Inc. |
Immuno-based retargeted endopeptidase activity assays
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
WO2010111702A1
(en)
|
2009-03-27 |
2010-09-30 |
The Research Foundation Of State University Of New York |
Methods for preventing and treating angioedema
|
AU2010234849B2
(en)
|
2009-03-30 |
2017-06-22 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
NZ596218A
(en)
|
2009-04-08 |
2013-07-26 |
Olle Hernell |
Bssl antagonists for treatment of inflammatory diseases
|
MX343049B
(es)
|
2009-04-09 |
2016-10-21 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
RU2595379C2
(ru)
|
2009-04-16 |
2016-08-27 |
АббВай Биотерапеутикс Инк. |
АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
PT2426148E
(pt)
|
2009-04-27 |
2015-10-26 |
Kyowa Hakko Kirin Co Ltd |
Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
|
MX2011011338A
(es)
|
2009-04-27 |
2012-04-19 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
|
EP3275900A1
(de)
|
2009-04-27 |
2018-01-31 |
Novartis AG |
Zusammensetzungen und verfahren zur förderung des muskelwachstums
|
CA2760642A1
(en)
|
2009-05-01 |
2010-11-04 |
The University Of Tokyo |
Anti-cadherin antibody
|
PT2448970E
(pt)
|
2009-05-04 |
2014-10-20 |
Abbvie Res B V |
Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada
|
EP2427203B1
(de)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f-antikörper und deren verwendung
|
EP2270053A1
(de)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanisierte AXL-Antikörper
|
BRPI1011195B1
(pt)
*
|
2009-05-20 |
2020-10-13 |
Novimmune S.A |
métodos para produzir uma coleção de ácidos nucleicos
|
EP2435475B1
(de)
|
2009-05-26 |
2018-10-17 |
Icahn School of Medicine at Mount Sinai |
Mittels zyklischer verabreichung erzeugte monoklonale antikörper gegen influenzavirus und ihre anwendung
|
US20120141501A1
(en)
|
2009-05-29 |
2012-06-07 |
Forerunner Pharma Research Co. Ltd |
Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
|
JP5804521B2
(ja)
|
2009-05-29 |
2015-11-04 |
モルフォシス・アー・ゲー |
コレクション及びその使用方法
|
RU2765240C2
(ru)
|
2009-06-03 |
2022-01-27 |
Иммьюноджен, Инк. |
Способы конъюгации
|
SG10201403327WA
(en)
|
2009-06-17 |
2014-10-30 |
Abbvie Biotherapeutics Inc |
Anti-vegf antibodies and their uses
|
MX2012000121A
(es)
|
2009-06-22 |
2012-03-07 |
Medimmune Llc |
Regiones fc modificadas para la conjugacion especifica del sitio.
|
WO2010151632A1
(en)
|
2009-06-25 |
2010-12-29 |
Bristol-Myers Squibb Company |
Protein purifacation by caprylic acid (octanoic acid ) precipitation
|
EP2448972A4
(de)
*
|
2009-06-30 |
2012-11-28 |
Res Dev Foundation |
Immunoglobulin-fc-polypeptide
|
EP2448966B1
(de)
|
2009-07-03 |
2018-11-14 |
Avipep Pty Ltd |
Immunkonjugate und verfahren zu ihrer herstellung
|
IE20090514A1
(en)
|
2009-07-06 |
2011-02-16 |
Opsona Therapeutics Ltd |
Humanised antibodies and uses therof
|
US9217157B2
(en)
|
2009-07-27 |
2015-12-22 |
Icahn School Of Medicine At Mount Sinai |
Recombinant influenza viruses and uses thereof
|
EP2459585A1
(de)
|
2009-07-30 |
2012-06-06 |
Mount Sinai School of Medicine |
Influenzaviren und ihre verwendung
|
SG178190A1
(en)
|
2009-07-31 |
2012-03-29 |
Shin Maeda |
Cancer metastasis inhibitor
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
CN102574917A
(zh)
|
2009-08-17 |
2012-07-11 |
株式会社未来创药研究所 |
含有抗hb-egf抗体作为有效成分的药物组合物
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
CN102741288B
(zh)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
治疗用dll4结合蛋白
|
JP2013503607A
(ja)
|
2009-09-01 |
2013-02-04 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
EP2477654A4
(de)
|
2009-09-14 |
2013-01-23 |
Abbott Lab |
Verfahren zur behandlung von schuppenflechte
|
WO2011032181A2
(en)
*
|
2009-09-14 |
2011-03-17 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
WO2011032204A1
(en)
|
2009-09-15 |
2011-03-24 |
Csl Limited |
Treatment of neurological conditions
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
US20120183546A1
(en)
|
2009-09-23 |
2012-07-19 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
WO2011037983A1
(en)
|
2009-09-23 |
2011-03-31 |
Medarex, Inc. |
Cation exchange chromatography
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
WO2011040973A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
|
EP2483316A1
(de)
|
2009-10-02 |
2012-08-08 |
Ludwig Institute for Cancer Research Ltd. |
Anti-fibroblastenaktivierungsprotein-antikörper, verfahren und verwendung
|
JP2013506709A
(ja)
|
2009-10-06 |
2013-02-28 |
イミュノジェン・インコーポレーテッド |
有効なコンジュゲートおよび親水性リンカー
|
DK2486141T3
(en)
|
2009-10-07 |
2018-04-23 |
Macrogenics Inc |
FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
ES2826883T3
(es)
|
2009-10-14 |
2021-05-19 |
Janssen Biotech Inc |
Métodos de maduración por afinidad de anticuerpos
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
CN102781963B
(zh)
|
2009-10-27 |
2018-02-16 |
Ucb医药有限公司 |
功能修饰性NAv1.7抗体
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
EP2493929B1
(de)
|
2009-10-28 |
2017-08-16 |
AbbVie Biotherapeutics Inc. |
Anti-egfr-antikörper und deren verwendungen
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
EA029283B1
(ru)
|
2009-10-30 |
2018-03-30 |
Янссен Байотек, Инк. |
Антагонисты il-17a
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
EP2496600A1
(de)
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
CN102640001A
(zh)
|
2009-11-05 |
2012-08-15 |
诺瓦提斯公司 |
预测纤维化进展的生物标记物
|
EP2496604B1
(de)
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Antikörper gegen hunde-cd20
|
CA2780024A1
(en)
|
2009-11-11 |
2011-05-19 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
HUE035508T2
(en)
|
2009-11-17 |
2018-05-02 |
Squibb & Sons Llc |
Procedures for Increased Protein Production
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
US20130183326A9
(en)
*
|
2009-11-20 |
2013-07-18 |
St. Jude Children's Research Hospital |
Methods and compositions for modulating the activity of the interleukin-35 receptor complex
|
WO2011067711A2
(en)
|
2009-12-01 |
2011-06-09 |
Compugen Ltd |
Novel heparanase splice variant
|
EP2510001B1
(de)
|
2009-12-08 |
2015-12-02 |
AbbVie Deutschland GmbH & Co KG |
Monoklonale antikörper gegen das rgm-a-protein zur behandlung von degenerationen der retinalen nervenfaserschicht
|
IN2012DN04908A
(de)
|
2009-12-09 |
2015-09-25 |
Inst Nat Sante Rech Med |
|
WO2011084496A1
(en)
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
CA2784610C
(en)
|
2009-12-23 |
2020-07-14 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
US9005579B2
(en)
|
2010-01-05 |
2015-04-14 |
Contrafect Corporation |
Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
MX2012008085A
(es)
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
EP2530109A4
(de)
|
2010-01-29 |
2013-08-28 |
Toray Industries |
Harzfolie auf polymilchsäurebasis
|
EP2533810B1
(de)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20-antikörper und ihre verwendung
|
MX2012009318A
(es)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Metodos y compuestos para el crecimiento muscular.
|
US8815211B2
(en)
|
2010-02-10 |
2014-08-26 |
Fujifilm Ri Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
NZ601743A
(en)
|
2010-02-12 |
2014-11-28 |
Oncomed Pharm Inc |
Methods for identifying and isolating cells expressing a polypeptide
|
WO2011103330A2
(en)
|
2010-02-17 |
2011-08-25 |
The Johns Hopkins University |
Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
|
KR20120132506A
(ko)
|
2010-02-18 |
2012-12-05 |
마운트 시나이 스쿨 오브 메디슨 |
인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신
|
KR20190114019A
(ko)
|
2010-02-24 |
2019-10-08 |
이뮤노젠 아이엔씨 |
엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
|
RU2016146198A
(ru)
|
2010-03-02 |
2018-12-19 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
US20130004519A1
(en)
|
2010-03-05 |
2013-01-03 |
Ruth Chiquet-Ehrismann |
Smoci, tenascin-c and brain cancers
|
SG183542A1
(en)
|
2010-03-12 |
2012-10-30 |
Immunogen Inc |
Cd37-binding molecules and immunoconjugates thereof
|
BR112012023895A2
(pt)
|
2010-03-17 |
2016-11-29 |
Abbott Res Bv |
composições de anti-fator de crescimento do nervo (ngf)
|
WO2011117653A1
(en)
|
2010-03-25 |
2011-09-29 |
Ucb Pharma S.A. |
Disulfide stabilized dvd-lg molecules
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CA2794483C
(en)
|
2010-03-26 |
2020-07-07 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
AU2011235220B2
(en)
|
2010-03-30 |
2016-03-10 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
EP2558498B1
(de)
|
2010-04-13 |
2016-10-12 |
Celldex Therapeutics, Inc. |
Humane cd27-bindende antikörper und ihre verwendung
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
EP2380909A1
(de)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An Brustkrebs beteiligtes Protein PTK-7
|
MX340696B
(es)
|
2010-04-30 |
2016-07-21 |
Alexion Pharma Inc |
Anticuerpos anti-c5a y metodos para usar los anticuerpos.
|
WO2011137319A2
(en)
|
2010-04-30 |
2011-11-03 |
Centocor Ortho Biotech Inc. |
Stabilized fibronectin domain compositions, methods and uses
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
JP2013533211A
(ja)
|
2010-05-04 |
2013-08-22 |
メリマック ファーマシューティカルズ インコーポレーティッド |
上皮成長因子受容体(egfr)に対する抗体およびその使用
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
IL208820A0
(en)
|
2010-10-19 |
2011-01-31 |
Rachel Teitelbaum |
Biologic female contraceptives
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
CN102883748A
(zh)
|
2010-05-07 |
2013-01-16 |
爱克索马技术有限公司 |
治疗IL-1β相关状况的方法
|
ES2635594T3
(es)
|
2010-05-14 |
2017-10-04 |
Abbvie Inc. |
Proteínas de unión a IL-1
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
WO2011149051A1
(ja)
|
2010-05-28 |
2011-12-01 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
EP3327035A1
(de)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
|
ES2706913T3
(es)
|
2010-06-25 |
2019-04-01 |
Univ Aston |
Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
JP5744196B2
(ja)
|
2010-07-09 |
2015-07-08 |
クルセル ホランド ベー ヴェー |
抗ヒト呼吸器多核体ウイルス(rsv)抗体および使用の方法
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
JP6266343B2
(ja)
|
2010-07-16 |
2018-01-24 |
アディマブ, エルエルシー |
抗体ライブラリー
|
CA2805653A1
(en)
|
2010-07-20 |
2012-01-26 |
Cephalon Australia Pty Ltd |
Anti-il-23 heterodimer specific antibodies
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
NZ607480A
(en)
|
2010-08-03 |
2014-10-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
JP6121903B2
(ja)
|
2010-08-19 |
2017-04-26 |
ゾエティス・ベルジャム・エス・アー |
抗ngf抗体およびその使用
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
DK2606070T3
(en)
|
2010-08-20 |
2017-03-27 |
Novartis Ag |
Antibodies for the epidermal growth factor receptor 3 (HER3)
|
EP2608803A4
(de)
|
2010-08-26 |
2014-01-15 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
US20130224192A1
(en)
|
2010-09-02 |
2013-08-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for the prognosis of the progression of cancer
|
RU2551963C2
(ru)
|
2010-09-09 |
2015-06-10 |
Пфайзер Инк. |
Молекулы, связывающиеся с 4-1вв
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
DK2616090T3
(da)
|
2010-09-17 |
2023-09-18 |
Takeda Pharmaceuticals Co |
Stabilisering af immunoglobuliner gennem vandig formulering med histidin ved svag syre til neutral ph
|
EP2616100B1
(de)
|
2010-09-17 |
2016-08-31 |
Compugen Ltd. |
Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
|
EP2622091B1
(de)
|
2010-09-23 |
2019-03-13 |
Precision Biologics, Inc. |
Peptidomimetika gegen darm- und bauchspeicheldrüsenkrebs
|
EP3223014B1
(de)
*
|
2010-09-24 |
2018-12-05 |
Full Spectrum Genetics, Inc. |
Verfahren zur analyse von bindungsinteraktionen
|
KR102595129B1
(ko)
|
2010-09-29 |
2023-10-31 |
어젠시스 인코포레이티드 |
191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
WO2012044992A2
(en)
|
2010-09-30 |
2012-04-05 |
Agency For Science, Technology And Research (A*Star) |
Methods and reagents for detection and treatment of esophageal metaplasia
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−il12rベータ1抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
SG189322A1
(en)
|
2010-10-13 |
2013-05-31 |
Janssen Biotech Inc |
Human oncostatin m antibodies and methods of use
|
AU2011323784A1
(en)
|
2010-10-25 |
2013-05-30 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
US20130337470A1
(en)
|
2010-10-25 |
2013-12-19 |
Biogen Idec Ma Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
|
NZ623347A
(en)
|
2010-10-29 |
2014-07-25 |
Daiichi Sankyo Co Ltd |
Novel anti-dr5 antibody
|
PT2634194T
(pt)
|
2010-10-29 |
2018-10-19 |
Perseus Proteomics Inc |
Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização
|
SG10201407036YA
(en)
|
2010-11-05 |
2014-12-30 |
Transbio Ltd |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
EP2640738A1
(de)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Antimykotische wirkstoffe
|
WO2012067188A1
(ja)
|
2010-11-18 |
2012-05-24 |
国立大学法人岡山大学 |
ヒト型抗体を産生するb細胞の作製方法
|
MX353795B
(es)
|
2010-11-19 |
2018-01-30 |
Morphosys Ag |
Coleccion y metodos para su uso.
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
EA201390611A1
(ru)
|
2010-11-24 |
2014-01-30 |
Глаксо Груп Лимитед |
Мультиспецифические антигенсвязывающие белки, направленные на hgf
|
CN103328632A
(zh)
|
2010-11-30 |
2013-09-25 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
EP4303237A3
(de)
|
2010-11-30 |
2024-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Zytotoxizitätsinduzierendes therapeutikum
|
BR112013015508B1
(pt)
|
2010-12-20 |
2022-04-05 |
Medimmune Limited |
Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
WO2012085069A2
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Detection of a polypeptide dimer by a bivalent binding agent
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012085064A1
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
|
WO2012085113A1
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Binding agent
|
EP2658971A1
(de)
|
2010-12-28 |
2013-11-06 |
XOMA Technology Ltd. |
Zelloberflächendisplay mit pdz-domänen
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
KR101950306B1
(ko)
|
2011-01-14 |
2019-02-20 |
유씨비 바이오파마 에스피알엘 |
Il-17a 및 il-17f에 결합하는 항체 분자
|
EP2668207A4
(de)
|
2011-01-24 |
2015-06-10 |
Univ Singapore |
Aus krankheitserregenden mykobakterien gewonnene mannose-gekapselte lipoarabinomannan-antigen-bindende proteine
|
EP2668210B1
(de)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und ihre verwendungen
|
US9732143B2
(en)
|
2011-02-03 |
2017-08-15 |
Xoma Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
US8952132B2
(en)
|
2011-02-07 |
2015-02-10 |
Research Development Foundation |
Engineered immunoglobulin FC polypeptides
|
EP3666289A1
(de)
|
2011-02-15 |
2020-06-17 |
ImmunoGen, Inc. |
Zytotoxische benzodiazepinderivate
|
SG192945A1
(en)
|
2011-02-25 |
2013-09-30 |
Chugai Pharmaceutical Co Ltd |
Fcgriib-specific fc antibody
|
WO2012133782A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
US9624294B2
(en)
|
2011-03-14 |
2017-04-18 |
Cellmid Limited |
Antibody recognizing N-domain of midkine
|
JP2014510730A
(ja)
|
2011-03-16 |
2014-05-01 |
サノフイ |
デュアルv領域抗体様タンパク質の使用
|
TR201902180T4
(tr)
|
2011-03-29 |
2019-03-21 |
Immunogen Inc |
Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
|
SG193997A1
(en)
|
2011-03-29 |
2013-11-29 |
Immunogen Inc |
Process for manufacturing conjugates of improved homogeneity
|
MX356426B
(es)
|
2011-04-04 |
2018-05-29 |
Univ Iowa Res Found |
Metodos para mejorar inmunogenicidad de vacuna.
|
JP5908972B2
(ja)
|
2011-04-07 |
2016-04-26 |
アムジエン・インコーポレーテツド |
新規な抗原結合タンパク質
|
AU2012241373B2
(en)
|
2011-04-15 |
2016-06-09 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
EP2700652B1
(de)
|
2011-04-18 |
2018-12-19 |
The University of Tokyo |
Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
|
DK2699264T3
(en)
|
2011-04-20 |
2018-06-25 |
Medimmune Llc |
ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
|
EP2699597B1
(de)
|
2011-04-21 |
2016-06-01 |
Garvan Institute of Medical Research |
Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür
|
LT2703486T
(lt)
|
2011-04-25 |
2018-05-25 |
Daiichi Sankyo Company, Limited |
Anti-b7-h3 antikūnas
|
KR101833465B1
(ko)
|
2011-05-06 |
2018-02-28 |
넥스베트 오스트레일리아 피티와이 리미티드 |
항신경 성장 인자 항체 및 그의 제조방법과 이용방법
|
DK3498732T3
(da)
|
2011-05-06 |
2022-01-17 |
Zoetis Services Llc |
Antistoffer mod anti-nervevækstfaktor og fremgangsmåder til fremstilling og anvendelse deraf
|
GB201114858D0
(en)
|
2011-08-29 |
2011-10-12 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of using the same
|
SG10201500953YA
(en)
|
2011-05-06 |
2015-04-29 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of preparing and using the same
|
WO2012153707A1
(ja)
|
2011-05-09 |
2012-11-15 |
株式会社ペルセウスプロテオミクス |
トランスフェリン受容体を特異的に認識できる抗体
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
IL295205A
(en)
|
2011-05-17 |
2022-10-01 |
Univ Rockefeller |
Neutralizing antibodies against the human immunodeficiency virus and methods of using them
|
KR102030531B1
(ko)
|
2011-05-21 |
2019-10-10 |
마크로제닉스, 인크. |
탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
JP6342325B2
(ja)
|
2011-05-25 |
2018-06-13 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
炎症性障害の治療のための抗kir抗体
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2012170807A2
(en)
|
2011-06-10 |
2012-12-13 |
Medimmune, Llc |
Anti-pseudomonas psl binding molecules and uses thereof
|
AU2012266363A1
(en)
|
2011-06-10 |
2014-01-09 |
Corimmun Gmbh |
Binding compounds to human beta1-adrenoreceptor (beta1-AR) and their use in the measurement of auto-anti-beta1-AR antibodies
|
KR101822702B1
(ko)
|
2011-06-13 |
2018-01-26 |
씨에스엘 리미티드 |
G-csfr에 대한 항체 및 이의 용도
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
MX350954B
(es)
|
2011-06-21 |
2017-09-26 |
Immunogen Inc |
Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
|
WO2013003625A2
(en)
|
2011-06-28 |
2013-01-03 |
Oxford Biotherapeutics Ltd. |
Antibodies
|
WO2013001369A2
(en)
|
2011-06-28 |
2013-01-03 |
Oxford Biotherapeutics Ltd. |
Therapeutic and diagnostic target
|
CA2839539C
(en)
|
2011-06-30 |
2021-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
CA2836855C
(en)
|
2011-06-30 |
2020-07-14 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
US9365651B2
(en)
|
2011-07-01 |
2016-06-14 |
Novartis Ag |
Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
MX349198B
(es)
|
2011-07-15 |
2017-07-18 |
Oncomed Pharmaceuticals Inc * |
Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
EA028886B1
(ru)
|
2011-07-27 |
2018-01-31 |
Глаксо Груп Лимитед |
ОТДЕЛЬНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ПРОТИВ VEGF, СЛИТЫЕ С Fc-ДОМЕНАМИ
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
JP6101205B2
(ja)
|
2011-08-23 |
2017-03-22 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
SG11201400222RA
(en)
|
2011-08-30 |
2014-03-28 |
Nvip Pty Ltd |
Caninised tumour necrosis factor antibodies and methods of using the same
|
EP2753697A1
(de)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
|
US10018630B2
(en)
|
2011-09-07 |
2018-07-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell isolation
|
CA2848074A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
WO2013043729A1
(en)
|
2011-09-20 |
2013-03-28 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
IN2014CN02113A
(de)
|
2011-09-21 |
2015-05-29 |
Fujirebio Kk |
|
JO3625B1
(ar)
|
2011-09-22 |
2020-08-27 |
Amgen Inc |
بروتينات رابطة للأنتيجين cd27l
|
HUE061002T2
(hu)
|
2011-09-23 |
2023-04-28 |
Mereo Biopharma 5 Inc |
VEGF/DLL4-kötõ ágensek és alkalmazásaik
|
CN110725009B
(zh)
|
2011-09-27 |
2024-01-30 |
詹森生物科技公司 |
具有可供选择的结合表面的基于iii型纤连蛋白重复的蛋白质支架
|
KR102528622B1
(ko)
|
2011-09-30 |
2023-05-04 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존성 결합 분자 라이브러리
|
AU2012315474B2
(en)
|
2011-09-30 |
2017-10-26 |
Teva Pharmaceuticals Australia Pty Ltd. |
Antibodies against TL1a and uses thereof
|
TW201726745A
(zh)
|
2011-09-30 |
2017-08-01 |
中外製藥股份有限公司 |
促進抗原消失的抗原結合分子
|
KR102492584B1
(ko)
|
2011-09-30 |
2023-01-27 |
추가이 세이야쿠 가부시키가이샤 |
표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP3939996A1
(de)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
JP2014530816A
(ja)
|
2011-10-14 |
2014-11-20 |
ノバルティスアーゲー |
Wnt経路関連疾患のための抗体および方法
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
EP3603671A3
(de)
|
2011-10-28 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Krebstammzellenspezifisches molekül
|
CA2852709A1
(en)
|
2011-10-28 |
2013-05-02 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
JP2015502741A
(ja)
|
2011-11-04 |
2015-01-29 |
ノバルティス アーゲー |
低比重リポタンパク質関連タンパク質6(lrp6)−半減期延長構築物
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
EP2776466B1
(de)
|
2011-11-11 |
2017-08-23 |
UCB Biopharma SPRL |
Albuminbindende antikörper und bindungsfragmenten davon
|
EP2797957B1
(de)
|
2011-11-23 |
2019-06-19 |
MedImmune, LLC |
Her3-spezifische bindungsmoleküle und verwendungen davon
|
RU2739792C1
(ru)
|
2011-11-30 |
2020-12-28 |
Чугаи Сейяку Кабусики Кайся |
Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
CN108341873B
(zh)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
AU2012352168C1
(en)
|
2011-12-14 |
2018-01-25 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
BR112014015111A2
(pt)
|
2011-12-21 |
2017-06-13 |
Novartis Ag |
composições e processos para anticorpos que se direcionam ao fator p
|
EP2794653B1
(de)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
EP2797955A2
(de)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
|
EP2800583A1
(de)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 und brustkrebs
|
WO2013104798A1
(en)
|
2012-01-12 |
2013-07-18 |
Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences |
Modulators of immune responses
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
PL2807192T3
(pl)
|
2012-01-27 |
2019-02-28 |
Abbvie Deutschland |
Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów
|
MX2014009289A
(es)
|
2012-02-01 |
2015-09-08 |
Compugen Ltd |
Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
|
MX366965B
(es)
|
2012-02-03 |
2019-07-31 |
Hoffmann La Roche |
Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
|
CN104271757B
(zh)
|
2012-02-06 |
2020-06-09 |
印希彼有限公司 |
Cd47抗体及其使用方法
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
DK2814842T3
(en)
|
2012-02-15 |
2018-12-10 |
Novo Nordisk As |
ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
WO2013120553A1
(en)
|
2012-02-15 |
2013-08-22 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
JP6138108B2
(ja)
|
2012-02-24 |
2017-05-31 |
中外製薬株式会社 |
FcγRIIBを介して抗原の消失を促進する抗原結合分子
|
EP2825200A4
(de)
|
2012-03-15 |
2015-08-26 |
Janssen Biotech Inc |
Menschliche anti-cd27-antikörper, verfahren und verwendungen
|
US9676857B2
(en)
|
2012-03-16 |
2017-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble engineered monomeric Fc
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
SG10201702842SA
(en)
|
2012-03-27 |
2017-06-29 |
Genentech Inc |
Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
CN104321430A
(zh)
|
2012-03-30 |
2015-01-28 |
第一三共株式会社 |
新颖的抗-siglec-15抗体
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
KR20150003251A
(ko)
|
2012-04-04 |
2015-01-08 |
가부시키가이샤 페르세우스 프로테오믹스 |
항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트
|
US9714298B2
(en)
|
2012-04-09 |
2017-07-25 |
Daiichi Sankyo Company, Limited |
Anti-FGFR2 antibodies and methods of use thereof for treating cancer
|
CN104768973B
(zh)
|
2012-04-27 |
2019-01-22 |
第一三共株式会社 |
抗robo4抗体
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
WO2013173364A2
(en)
|
2012-05-14 |
2013-11-21 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
MX362497B
(es)
|
2012-05-15 |
2019-01-21 |
Eisai Inc |
Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
EP2855521A4
(de)
|
2012-05-24 |
2016-03-02 |
Mountgate Group Ltd |
Zusammensetzungen und verfahren in zusammenhang mit der vorbeugung und behandlung von tollwutinfektion
|
EP3892638A1
(de)
|
2012-05-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur beseitigung von aggregierten antigenen
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ngf抗体およびその方法
|
KR20150018604A
(ko)
|
2012-06-06 |
2015-02-23 |
온코메드 파마슈티칼스, 인크. |
히포 경로를 조절하는 결합제 및 그의 용도
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AU2013277051B2
(en)
|
2012-06-22 |
2018-06-07 |
King's College London |
Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CA2871386A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
WO2014001557A1
(en)
|
2012-06-28 |
2014-01-03 |
Ucb Pharma S.A. |
A method for identifying compounds of therapeutic interest
|
EP2866831A1
(de)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
JP2015524816A
(ja)
|
2012-08-02 |
2015-08-27 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EA201990839A1
(ru)
|
2012-08-23 |
2019-08-30 |
Эдженсис, Инк. |
Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
|
WO2014030750A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
DK2889377T3
(da)
|
2012-08-24 |
2020-03-30 |
Chugai Pharmaceutical Co Ltd |
Fc?RIIb-Specifik Fc-regionsvariant
|
SG11201500938XA
(en)
|
2012-08-31 |
2015-04-29 |
Immunogen Inc |
Diagnostic assays and kits for detection of folate receptor 1
|
AU2013312211B2
(en)
|
2012-09-07 |
2018-03-29 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CN104797710A
(zh)
|
2012-09-27 |
2015-07-22 |
中外制药株式会社 |
Fgfr3融合基因和以其作为标靶的药物
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
NO2760138T3
(de)
|
2012-10-01 |
2018-08-04 |
|
|
ES2743423T3
(es)
|
2012-10-03 |
2020-02-19 |
Philogen Spa |
Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
|
RU2661083C2
(ru)
|
2012-10-04 |
2018-07-11 |
Иммуноджен, Инк. |
Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
|
KR102369419B1
(ko)
|
2012-10-11 |
2022-03-02 |
다이이찌 산쿄 가부시키가이샤 |
글리신아미드 화합물의 제조 방법
|
EP3679950A1
(de)
|
2012-10-12 |
2020-07-15 |
The Brigham and Women's Hospital, Inc. |
Verbesserung der immunreaktion
|
CN110294804B
(zh)
|
2012-10-15 |
2023-07-14 |
米迪缪尼有限公司 |
针对β淀粉样蛋白的抗体
|
DK2908912T3
(da)
|
2012-10-18 |
2020-10-26 |
Univ Rockefeller |
Bredt neutraliserende anti-hiv-antistoffer
|
EP2910573B1
(de)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
WO2014071282A1
(en)
|
2012-11-05 |
2014-05-08 |
Genzyme Corporation |
Compositions and methods for treating proteinopathies
|
JP6212497B2
(ja)
|
2012-11-08 |
2017-10-11 |
国立大学法人 宮崎大学 |
トランスフェリン受容体を特異的に認識できる抗体
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
EA031184B1
(ru)
|
2012-11-21 |
2018-11-30 |
Янссен Байотек, Инк. |
БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
SG11201503567SA
(en)
|
2012-12-05 |
2015-06-29 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
DK2928923T3
(da)
|
2012-12-10 |
2020-02-17 |
Biogen Ma Inc |
Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf
|
CN108641002A
(zh)
|
2012-12-18 |
2018-10-12 |
西奈山伊坎医学院 |
流感病毒疫苗及其用途
|
CA2891686A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
KR20150100715A
(ko)
|
2012-12-21 |
2015-09-02 |
앰플리뮨, 인크. |
항-h7cr 항체
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
AU2013202668B2
(en)
|
2012-12-24 |
2014-12-18 |
Adelaide Research & Innovation Pty Ltd |
Inhibition of cancer growth and metastasis
|
US10766960B2
(en)
|
2012-12-27 |
2020-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
WO2014106176A1
(en)
|
2012-12-28 |
2014-07-03 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
EP2951208B1
(de)
|
2013-02-01 |
2019-11-13 |
Kira Biotech Pty Limited |
Anti-cd83-antikörper und verwendung davon
|
SG11201506132PA
(en)
|
2013-02-06 |
2015-09-29 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
SG11201505762XA
(en)
|
2013-02-07 |
2015-08-28 |
Csl Ltd |
Il-11r binding proteins and uses thereof
|
CA2897682C
(en)
|
2013-02-08 |
2023-03-14 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US9901647B2
(en)
|
2013-02-28 |
2018-02-27 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
CA2902068C
(en)
|
2013-02-28 |
2023-10-03 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
EP3566750A3
(de)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Konjugate aus zellbindenden und zytotoxischen verbindungen
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
CA2906421C
(en)
|
2013-03-14 |
2022-08-16 |
George J. Dawson |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
US10093921B2
(en)
|
2013-03-14 |
2018-10-09 |
The Governing Council Of The University Of Toronto |
Scaffolded peptidic libraries and methods of making and screening the same
|
US20140286969A1
(en)
|
2013-03-15 |
2014-09-25 |
Abbvie Inc. |
Anti-egfr antibody drug conjugate formulations
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
JP2016515524A
(ja)
|
2013-03-15 |
2016-05-30 |
アッヴィ バイオテクノロジー リミテッド |
抗cd25抗体およびそれらの使用
|
JP6466904B2
(ja)
|
2013-03-15 |
2019-02-06 |
ヤンセン バイオテツク,インコーポレーテツド |
インターフェロンアルファ及びオメガ抗体アンタゴニスト
|
CN105121470A
(zh)
|
2013-03-15 |
2015-12-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
CN105143257B
(zh)
|
2013-03-15 |
2020-10-27 |
艾伯维生物医疗股份有限公司 |
Fc变体
|
EP2968589A1
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Aufreinigung eins antikörper-wirkstoff-konjugats (adc)
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
EP3424530A1
(de)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalente und monovalente multispezifische komplexe und deren verwendungen
|
PL2976361T3
(pl)
|
2013-03-18 |
2018-12-31 |
Biocerox Products B.V. |
Humanizowane przeciwciała anty-CD134 (OX40) i ich zastosowania
|
MX2015013703A
(es)
|
2013-03-27 |
2016-08-11 |
Cedars Sinai Medical Center |
Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.
|
WO2014163101A1
(ja)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Fc領域改変体
|
EP2981822B1
(de)
|
2013-05-06 |
2020-09-02 |
Scholar Rock, Inc. |
Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
|
EP2997378B1
(de)
|
2013-05-16 |
2018-08-08 |
Kyoto University |
Verfahren zur bestimmung der prognose von krebs
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
NZ753995A
(en)
|
2013-05-30 |
2022-07-01 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
JPWO2014208482A1
(ja)
|
2013-06-24 |
2017-02-23 |
中外製薬株式会社 |
ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
EP4105236A1
(de)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen
|
MX2016001233A
(es)
|
2013-08-01 |
2016-10-28 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas cd37.
|
CN113683695A
(zh)
|
2013-08-02 |
2021-11-23 |
辉瑞公司 |
抗cxcr4抗体及抗体-药物缀合物
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
WO2015023851A1
(en)
|
2013-08-14 |
2015-02-19 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled proteins and methods of use thereof
|
TN2016000057A1
(en)
|
2013-08-14 |
2017-07-05 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
WO2015026846A1
(en)
|
2013-08-19 |
2015-02-26 |
Biogen Idec Ma Inc. |
Control of protein glycosylation by culture medium supplementation and cell culture process parameters
|
CA2922478C
(en)
|
2013-08-26 |
2020-09-29 |
MabVax Therapeutics, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
IL293871A
(en)
|
2013-08-30 |
2022-08-01 |
Immunogen Inc |
Antibodies and assays for the detection of folate receptor 1
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
WO2015034052A1
(ja)
|
2013-09-05 |
2015-03-12 |
国立大学法人 宮崎大学 |
ヒトインテグリンa6b4と特異的に反応する抗体
|
US20160229922A1
(en)
|
2013-09-20 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
US10611794B2
(en)
|
2013-09-25 |
2020-04-07 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
SG10201803449VA
(en)
|
2013-09-27 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
EP3835422A1
(de)
|
2013-09-30 |
2021-06-16 |
Daiichi Sankyo Company, Limited |
Anti-lps-o11-antikörper
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
SG11201602522VA
(en)
|
2013-10-02 |
2016-04-28 |
Medimmune Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
CN105792844B
(zh)
|
2013-10-08 |
2021-03-02 |
第一三共株式会社 |
抗fgfr2抗体和另一药剂的组合
|
MX2016004411A
(es)
|
2013-10-08 |
2016-07-05 |
Immunogen Inc |
Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
|
CN105899226B
(zh)
|
2013-10-14 |
2020-05-12 |
詹森生物科技公司 |
半胱氨酸工程化iii型纤连蛋白域结合分子
|
EP3063317B1
(de)
|
2013-10-28 |
2020-06-03 |
DOTS Technology Corp. |
Allergennachweis
|
US9840555B2
(en)
|
2013-11-04 |
2017-12-12 |
Li-Te Chin |
Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
|
EP3065774B1
(de)
|
2013-11-06 |
2021-05-26 |
Janssen Biotech, Inc. |
Anti-ccl17-antikörper
|
WO2015068847A1
(ja)
|
2013-11-11 |
2015-05-14 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
US9803008B2
(en)
|
2013-11-28 |
2017-10-31 |
Csl Limited |
Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)
|
TWI702316B
(zh)
|
2013-12-04 |
2020-08-21 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
AU2014359085B2
(en)
|
2013-12-08 |
2017-11-02 |
Peptcell Limited |
HIV antigens and antibodies and compositions, methods and uses thereof
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
EP3082860B1
(de)
|
2013-12-18 |
2020-11-25 |
CSL Limited |
Verfahren zur behandlung von wunden
|
WO2015095809A1
(en)
|
2013-12-20 |
2015-06-25 |
Biogen Idec Ma Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
CA2935378C
(en)
|
2013-12-24 |
2023-04-18 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
KR20230078820A
(ko)
|
2013-12-25 |
2023-06-02 |
다이이찌 산쿄 가부시키가이샤 |
항 trop2 항체-약물 컨쥬게이트
|
JP6722455B2
(ja)
|
2013-12-27 |
2020-07-15 |
中外製薬株式会社 |
等電点の低い抗体の精製方法
|
EP3581179A1
(de)
|
2013-12-27 |
2019-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
|
BR112016013482B1
(pt)
|
2014-01-31 |
2022-04-19 |
Daiichi Sankyo Company, Limited |
Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica
|
RU2019119857A
(ru)
|
2014-02-20 |
2019-07-12 |
Аллерган, Инк. |
Антитела к компоненту комплемента c5
|
AU2015223056B2
(en)
|
2014-02-27 |
2020-10-01 |
Allergan, Inc. |
Complement Factor Bb antibodies
|
CA2938919C
(en)
|
2014-02-28 |
2020-12-29 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
SG11201607772WA
(en)
|
2014-03-31 |
2016-10-28 |
Debiopharm Int Sa |
Fgfr fusions
|
AU2015240599B2
(en)
|
2014-04-04 |
2020-11-19 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
HUE051676T2
(hu)
|
2014-04-08 |
2021-03-29 |
Boston Pharmaceuticals Inc |
Il-21-re specifikus kötõ molekulák és alkalmazásaik
|
IL311108A
(en)
|
2014-04-10 |
2024-04-01 |
Daiichi Sankyo Co Ltd |
Preparation method of drug conjugate - anti-HER3 antibody
|
JP2017512765A
(ja)
|
2014-04-11 |
2017-05-25 |
メディミューン,エルエルシー |
二重特異性her2抗体
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
US9753036B2
(en)
|
2014-04-29 |
2017-09-05 |
Edp Biotech Corporation |
Methods and compositions for screening and detecting biomarkers
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
NZ764877A
(en)
|
2014-06-04 |
2023-12-22 |
Biontech Res And Development Inc |
Human monoclonal antibodies to ganglioside gd2
|
SG10201810507WA
(en)
|
2014-06-06 |
2018-12-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
JP6791763B2
(ja)
|
2014-06-26 |
2020-11-25 |
イェール ユニバーシティーYale University |
疾患および障害の処置においてレナラーゼを制御する組成物および方法
|
EP3164129A1
(de)
|
2014-07-01 |
2017-05-10 |
Friedrich Miescher Institute for Biomedical Research |
Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
EP3172232B1
(de)
|
2014-07-17 |
2023-12-27 |
Novo Nordisk A/S |
Ortsgerichtete mutagenese von trem-1 antikörpern zur reduktion der viskosität.
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
EP4056993A1
(de)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur messung der viskosität einer proteinlösung
|
JP2017527562A
(ja)
|
2014-09-03 |
2017-09-21 |
イミュノジェン・インコーポレーテッド |
細胞毒性ベンゾジアゼピン誘導体
|
CN116514903A
(zh)
|
2014-09-03 |
2023-08-01 |
伊缪诺金公司 |
细胞毒性苯并二氮杂䓬衍生物
|
WO2016037985A1
(en)
|
2014-09-08 |
2016-03-17 |
Ruprecht-Karls-Universität Heidelberg |
Construct for the delivery of a molecule into the cytoplasm of a cell
|
AU2015315396B2
(en)
|
2014-09-09 |
2020-10-08 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
KR20230153495A
(ko)
|
2014-10-01 |
2023-11-06 |
메디뮨 리미티드 |
티카그렐로에 대한 항체 및 이의 사용 방법
|
JP2017531642A
(ja)
|
2014-10-03 |
2017-10-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
エボラ糖タンパク質に結合する抗体およびその使用
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
AU2015336931B2
(en)
|
2014-10-23 |
2021-04-29 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
EP3209697A4
(de)
|
2014-10-23 |
2018-05-30 |
La Trobe University |
Fn14-bindende proteine und verwendungen davon
|
US10011657B2
(en)
|
2014-10-31 |
2018-07-03 |
Abbvie Biotherapeutics Inc. |
Anti-CS1 antibodies and antibody drug conjugates
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
WO2016073401A1
(en)
|
2014-11-03 |
2016-05-12 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
LT3218406T
(lt)
|
2014-11-10 |
2021-06-25 |
Medimmune Limited |
Surišančios molekulės, specifiškos cd73 ir jų panaudojimas
|
EP3789403A1
(de)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
|
EP3218005B1
(de)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CN107406503B
(zh)
|
2014-11-18 |
2021-07-16 |
詹森药业有限公司 |
Cd47抗体、方法和用途
|
JP6788586B2
(ja)
|
2014-11-19 |
2020-11-25 |
コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. |
Hnlを用いる診断方法
|
CN107592813A
(zh)
|
2014-11-19 |
2018-01-16 |
伊缪诺金公司 |
用于制备细胞结合剂‑细胞毒性剂缀合物的方法
|
EP3725808A1
(de)
|
2014-11-21 |
2020-10-21 |
Bristol-Myers Squibb Company |
Antikörper gegen cd73 und verwendungen davon
|
EP3220900B1
(de)
|
2014-11-21 |
2020-09-23 |
University of Maryland, Baltimore |
Systeme zur gezielten strukturspezifischen partikelabgabe
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
SG11201704660YA
(en)
|
2014-12-08 |
2017-07-28 |
Berg Llc |
Use of markers including filamin a in the diagnosis and treatment of prostate cancer
|
JP2018506509A
(ja)
|
2014-12-09 |
2018-03-08 |
アッヴィ・インコーポレイテッド |
細胞透過性Bcl−xL阻害剤との抗体薬物コンジュゲート
|
JP2018508463A
(ja)
|
2014-12-09 |
2018-03-29 |
アッヴィ・インコーポレイテッド |
低細胞透過性を有するBcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
AU2015367224B2
(en)
|
2014-12-19 |
2020-12-10 |
Monash University |
IL-21 antibodies
|
AU2015365583B2
(en)
|
2014-12-19 |
2021-10-28 |
Regenesance B.V. |
Antibodies that bind human C6 and uses thereof
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体及びその使用
|
BR112017013385A2
(pt)
|
2014-12-23 |
2018-02-06 |
Bristol-Myers Squibb Company |
anticorpos para tigit
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
JP7152156B2
(ja)
|
2015-01-14 |
2022-10-12 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
抗lapモノクローナル抗体による癌の処置
|
AU2016209032A1
(en)
|
2015-01-23 |
2017-08-10 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
CA2975346A1
(en)
|
2015-02-02 |
2016-08-11 |
I2 Pharmaceuticals, Inc. |
Anti-surrogate light chain antibodies
|
AU2016219511B2
(en)
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
WO2016128349A1
(en)
|
2015-02-09 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
|
WO2016136933A1
(ja)
|
2015-02-27 |
2016-09-01 |
中外製薬株式会社 |
Il-6関連疾患治療用組成物
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
BR112017018468A2
(pt)
|
2015-03-06 |
2018-04-17 |
Csl Behring Recombinant Facility Ag |
fator de von willebrand modificado com meia-vida aumentada
|
US10695693B2
(en)
|
2015-03-13 |
2020-06-30 |
Bristol-Myers Squibb Company |
Use of alkaline washes during chromatography to remove impurities
|
SG11201707538XA
(en)
|
2015-03-17 |
2017-10-30 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
US20180105555A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
WO2016153978A1
(en)
|
2015-03-20 |
2016-09-29 |
Bristol-Myers Squibb Company |
Use of dextran to enhance protein purification by affinity chromatography
|
WO2016151557A1
(en)
|
2015-03-25 |
2016-09-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c5 convertase of the alternative complement pathway
|
US20180074077A1
(en)
|
2015-03-25 |
2018-03-15 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
ES2904573T3
(es)
|
2015-03-27 |
2022-04-05 |
Univ Southern California |
Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
|
KR102261618B1
(ko)
|
2015-03-31 |
2021-06-04 |
메디뮨 리미티드 |
신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
AU2016256486B2
(en)
|
2015-04-29 |
2021-09-23 |
University Of South Australia |
Compositions and methods for administering antibodies
|
TW201704263A
(zh)
|
2015-05-01 |
2017-02-01 |
梅迪繆思有限公司 |
新穎之噬菌體呈現庫、其成員及其用途
|
WO2016179518A2
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
BR112017023798A2
(pt)
|
2015-05-06 |
2018-10-16 |
Janssen Biotech Inc |
domínios fibronectina tipo iii de ligação a antígeno prostático específico de membrana
|
TWI820377B
(zh)
|
2015-05-07 |
2023-11-01 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
EP3095465A1
(de)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
|
UA124143C2
(uk)
|
2015-05-20 |
2021-07-28 |
Янссен Байотек, Інк. |
Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень
|
EA039951B1
(ru)
|
2015-05-27 |
2022-03-31 |
Юсб Биофарма Спрл |
Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
|
PE20180193A1
(es)
|
2015-05-29 |
2018-01-26 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
US10711064B2
(en)
|
2015-06-04 |
2020-07-14 |
University Of Southern California |
Lym-1 and Lym-2 targeted CAR cell immunotherapy
|
EA201792561A1
(ru)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
|
US10723793B2
(en)
|
2015-06-12 |
2020-07-28 |
Ludwig Institute For Cancer Research, Ltd. |
TGF-β3 specific antibodies and methods and uses thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
CA2990406A1
(en)
|
2015-06-22 |
2016-12-29 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
PE20181090A1
(es)
|
2015-06-24 |
2018-07-09 |
Janssen Biotech Inc |
Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
|
US11009509B2
(en)
|
2015-06-24 |
2021-05-18 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
KR20180021723A
(ko)
|
2015-06-29 |
2018-03-05 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 선택적 제조 방법
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
DK3313884T3
(da)
|
2015-06-29 |
2021-02-22 |
Immunogen Inc |
Anti-cd123-antistoffer og konjugater og derivater deraf
|
EP3319936A4
(de)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
Brückenlinker zur konjugation von zellbindenden molekülen
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Fgf21関連障害を処置する方法
|
EA201890434A1
(ru)
|
2015-08-05 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела к cd154 и способы их применения
|
JP2018528191A
(ja)
|
2015-08-19 |
2018-09-27 |
ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー |
抗体を生成する新規な方法
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
SI3347377T1
(sl)
|
2015-09-09 |
2021-06-30 |
Novartis Ag |
Protitelesa, ki vežejo timusni stromalni limfopoietin (tslp) in postopki uporabe protiteles
|
US10221249B2
(en)
*
|
2015-09-10 |
2019-03-05 |
Affigen, Llc |
Method of making patient specific anti-idiotype antibodies
|
JP6880006B2
(ja)
|
2015-09-17 |
2021-06-02 |
イミュノジェン, インコーポレイテッド |
抗folr1免疫複合体を含む治療組み合わせ
|
MY197562A
(en)
|
2015-09-21 |
2023-06-23 |
Aptevo Res & Development Llc |
Cd3 binding polypeptides
|
AU2016326721C1
(en)
|
2015-09-23 |
2021-06-03 |
Cytoimmune Therapeutics, Inc. |
FLT3 directed car cells for immunotherapy
|
SG10201911226QA
(en)
|
2015-09-23 |
2020-01-30 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
SG11201802352VA
(en)
|
2015-09-24 |
2018-04-27 |
Daiichi Sankyo Co Ltd |
Anti-garp antibody
|
RU2638457C2
(ru)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
|
CN108368510B
(zh)
|
2015-09-30 |
2023-09-01 |
詹森生物科技公司 |
特异性结合人cd40的激动性抗体和使用方法
|
RU2754683C2
(ru)
|
2015-10-27 |
2021-09-06 |
Юсб Биофарма Срл |
Способы лечения с использованием анти-il-17a антител
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
SI3370770T1
(sl)
|
2015-11-03 |
2021-03-31 |
Janssen Biotech, Inc. |
Subkutane formulacije protiteles proti CD38 in njihove uporabe
|
SG10202103712VA
(en)
|
2015-11-10 |
2021-05-28 |
Medimmune Llc |
Binding molecules specific for asct2 and uses thereof
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
US11213586B2
(en)
|
2015-11-19 |
2022-01-04 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
|
CN107406504B
(zh)
|
2015-11-19 |
2021-04-30 |
蔡则玲 |
Ctla-4抗体及其用途
|
JP2019501124A
(ja)
|
2015-11-30 |
2019-01-17 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
JP6983779B2
(ja)
|
2015-11-30 |
2021-12-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
|
JP6849694B2
(ja)
|
2015-11-30 |
2021-03-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
抗ヒトip−10抗体およびそれらの使用
|
JP2019500327A
(ja)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
WO2017096051A1
(en)
|
2015-12-02 |
2017-06-08 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
KR20180087430A
(ko)
|
2015-12-17 |
2018-08-01 |
얀센 바이오테크 인코포레이티드 |
Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
|
KR20180089510A
(ko)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
CD32b를 표적화하는 항체 및 그의 사용 방법
|
EP3184544A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein-v-inhibitoren zur verwendung als koagulansien
|
WO2017118761A1
(en)
|
2016-01-08 |
2017-07-13 |
Iontas Ltd |
Binding members with altered diversity scaffold domains
|
WO2017120523A2
(en)
|
2016-01-08 |
2017-07-13 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
WO2017121880A1
(en)
|
2016-01-15 |
2017-07-20 |
Philogen S.P.A |
Intestinal antigens for pharmacodelivery applications
|
EP3405492B1
(de)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
CA3013125A1
(en)
|
2016-02-05 |
2017-08-10 |
Immunogen, Inc. |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
GB201602413D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Method
|
CN116920085A
(zh)
|
2016-02-12 |
2023-10-24 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
EP3416479A1
(de)
|
2016-02-16 |
2018-12-26 |
Regeneron Pharmaceuticals, Inc. |
Nichtmenschliche tiere mit mutiertem kynureninase-gen
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
EP3423489A1
(de)
|
2016-03-04 |
2019-01-09 |
The Rockefeller University |
Antikörper gegen cd40 mit erhöhter agonistischer aktivität
|
AU2017231833B2
(en)
|
2016-03-10 |
2024-03-14 |
Viela Bio, Inc. |
ILT7 binding molecules and methods of using the same
|
KR20230152153A
(ko)
|
2016-03-10 |
2023-11-02 |
악셀레론 파마 인코포레이티드 |
액티빈 타입 2 수용체 결합 단백질 및 이의 용도
|
WO2017159287A1
(ja)
|
2016-03-14 |
2017-09-21 |
中外製薬株式会社 |
癌の治療に用いるための細胞傷害誘導治療剤
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス,インコーポレイティド |
NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
|
WO2017161067A1
(en)
|
2016-03-16 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc |
Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
|
CA3016383A1
(en)
|
2016-03-16 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc |
Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
|
KR20220153109A
(ko)
|
2016-03-17 |
2022-11-17 |
세다르스-신나이 메디칼 센터 |
Rnaset2를 통한 염증성 장 질환의 진단 방법
|
WO2017158101A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
DK3219727T3
(da)
|
2016-03-17 |
2021-01-04 |
Tillotts Pharma Ag |
Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
|
EP3430041B1
(de)
|
2016-03-17 |
2023-05-24 |
Numab Innovation AG |
Anti-tnf-alpha-antikörper und funktionale fragmente davon
|
JP7184746B2
(ja)
|
2016-03-17 |
2022-12-06 |
ヌマブ イノヴェイション アーゲー |
抗TNFα抗体およびそれらの機能的断片
|
PT3219726T
(pt)
|
2016-03-17 |
2020-12-15 |
Tillotts Pharma Ag |
Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
|
AU2017239038A1
(en)
|
2016-03-22 |
2018-10-04 |
Bionomics Inc |
Administration of an anti-LGR5 monoclonal antibody
|
EP3436477A2
(de)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von psoriasis mit erhöhter intervalldosierung von anti-il12- und/oder -23-antikörper
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
JP7184751B2
(ja)
|
2016-04-15 |
2022-12-06 |
イミュネクスト インコーポレイテッド |
抗ヒトvista抗体およびその使用
|
BR112018071307A2
(pt)
|
2016-04-18 |
2019-02-26 |
Celldex Therapeutics, Inc. |
anticorpos agonistas que ligam cd40 humana e usos dos mesmos
|
KR102417687B1
(ko)
|
2016-05-09 |
2022-07-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Tl1a 항체 및 그의 용도
|
KR20230028574A
(ko)
|
2016-05-17 |
2023-02-28 |
애브비 바이오테라퓨틱스 인크. |
항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법
|
WO2017205465A2
(en)
|
2016-05-24 |
2017-11-30 |
Griswold Karl Edwin |
Antibodies and methods of making same
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
WO2017205745A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
UA123111C2
(uk)
|
2016-05-27 |
2021-02-17 |
Еббві Байотерапьютікс Інк. |
Антитіло до cd40 та його застосування
|
RU2745748C2
(ru)
|
2016-06-02 |
2021-03-31 |
Эббви Инк. |
Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
|
KR102461666B1
(ko)
|
2016-06-03 |
2022-11-01 |
얀센 바이오테크 인코포레이티드 |
혈청 알부민 결합 피브로넥틴 iii 형 도메인
|
PL3458479T3
(pl)
|
2016-06-08 |
2021-07-26 |
Abbvie Inc. |
Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
|
EP4218804A3
(de)
|
2016-06-13 |
2023-09-13 |
Scholar Rock, Inc. |
Verwendung von myostatinhemmern und kombinationstherapien
|
JP7237344B2
(ja)
|
2016-06-15 |
2023-03-13 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルス血球凝集素タンパク質及びその使用
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
US10662235B2
(en)
|
2016-06-21 |
2020-05-26 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type III domain binding molecules
|
EP3474895A1
(de)
|
2016-06-28 |
2019-05-01 |
UMC Utrecht Holding B.V. |
Behandlung von ige-vermittelten erkrankungen mit spezifisch cd38 bindenden antikörpern
|
SG11201811788SA
(en)
|
2016-07-06 |
2019-01-30 |
Celgene Corp |
Antibodies with low immunogenicity and uses thereof
|
CA3030219A1
(en)
|
2016-07-07 |
2018-01-11 |
Berg Llc |
Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
|
EP3481864A1
(de)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B.V. |
Anti-apoc3-antikörper und verfahren zur verwendung davon
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
CA3026757A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
AU2017296237A1
(en)
|
2016-07-15 |
2019-01-03 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
|
JP2019521171A
(ja)
|
2016-07-20 |
2019-07-25 |
ヒブリジェニクス・エスアー |
抗cd38薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用
|
AU2017300040A1
(en)
|
2016-07-22 |
2019-01-24 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
TREM2 cleavage modulators and uses thereof
|
US20190330318A1
(en)
|
2016-07-25 |
2019-10-31 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
EP3491022A1
(de)
|
2016-07-29 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
|
WO2018027124A1
(en)
|
2016-08-05 |
2018-02-08 |
Medimmune, Llc |
Anti-o2 antibodies and uses thereof
|
JP2019530646A
(ja)
|
2016-08-12 |
2019-10-24 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
タンパク質精製法
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
KR102587941B1
(ko)
|
2016-08-12 |
2023-10-11 |
얀센 바이오테크 인코포레이티드 |
향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
TW201825511A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現免疫檢查點調節子的溶瘤病毒
|
MA46236A
(fr)
|
2016-09-14 |
2019-07-24 |
Janssen Biotech Inc |
Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
|
AU2017326329B2
(en)
|
2016-09-14 |
2023-10-26 |
Abbvie Biotherapeutics Inc. |
Anti-pd-1 antibodies and their uses
|
JP7051826B2
(ja)
|
2016-09-23 |
2022-04-11 |
シーエスエル、リミテッド |
凝固因子結合タンパク質及びその使用
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
MA46366A
(fr)
|
2016-09-30 |
2019-08-07 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
|
JP2019535015A
(ja)
|
2016-10-03 |
2019-12-05 |
アボット・ラボラトリーズAbbott Laboratories |
患者サンプルにおけるgfap状況を評価する改善された方法
|
US20190330368A1
(en)
|
2016-10-07 |
2019-10-31 |
Daiichi Sankyo Company, Limited |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
WO2018071500A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
CN109996560A
(zh)
|
2016-10-13 |
2019-07-09 |
麻省理工学院 |
结合寨卡病毒包膜蛋白的抗体及其用途
|
EP3312290A1
(de)
|
2016-10-18 |
2018-04-25 |
Ipsen Biopharm Limited |
Zellulärer vamp-spaltungstest
|
SG11201903063UA
(en)
|
2016-10-19 |
2019-05-30 |
Medimmune Llc |
Anti-o1 antibodies and uses thereof
|
CN110121509A
(zh)
|
2016-10-26 |
2019-08-13 |
西达-赛奈医疗中心 |
中和抗tl1a单克隆抗体
|
SG11201903842YA
(en)
|
2016-11-02 |
2019-05-30 |
Immunogen Inc |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
WO2018083237A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Operations Inc. |
Novel anti-py520-ddr1 antibodies
|
WO2018083240A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Gmbh |
Novel anti-py796-ddr1 antibodies
|
WO2018083235A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Gmbh |
Novel anti-py513-ddr1 antibodies
|
WO2018083238A1
(en)
|
2016-11-03 |
2018-05-11 |
Roche Diagnostics Gmbh |
Novel anti-py792-ddr1 antibodies
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
NZ754407A
(en)
|
2016-11-09 |
2023-01-27 |
Philogen Spa |
Il2 and tnf mutant immunoconjugates
|
EP3538550A1
(de)
|
2016-11-10 |
2019-09-18 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Or10h1-modulatoren und verwendungen davon
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
EP3888691A1
(de)
|
2016-11-14 |
2021-10-06 |
Hangzhou Dac Biotech Co., Ltd. |
Konjugationslinker, zellbindende molekül-wirkstoffkonjugate mit den linkern, verfahren zur herstellung und verwendung solcher konjugate mit den linkern
|
EP3541422A4
(de)
|
2016-11-16 |
2020-05-06 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von schuppenflechte mit anti-il-23-spezifischem antikörper
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
EP4015532A1
(de)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73-antikörper und immunkonjugate
|
KR20190080949A
(ko)
|
2016-11-23 |
2019-07-08 |
바이오버라티브 테라퓨틱스 인크. |
응고 인자 ix 및 응고 인자 x에 결합하는 이중특이적 항체
|
AU2017364818A1
(en)
|
2016-11-28 |
2019-05-23 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
BR112019011651A2
(pt)
|
2016-12-07 |
2020-01-07 |
Agenus Inc. |
Anticorpos anti-cttla-4 e métodos de uso dos mesmos
|
EP3554535A4
(de)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
Pd-l1-bindende fibronectin-typ iii-domänen
|
US10611823B2
(en)
|
2016-12-14 |
2020-04-07 |
Hanssen Biotech, Inc |
CD137 binding fibronectin type III domains
|
EP3932432A1
(de)
|
2016-12-14 |
2022-01-05 |
Janssen Biotech, Inc. |
Cd8a-bindende fibronectin-typ-iii-domänen
|
MY198059A
(en)
|
2016-12-15 |
2023-07-31 |
Abbvie Biotherapeutics Inc |
Anti-ox40 antibodies and their uses
|
MX2019006866A
(es)
|
2016-12-16 |
2019-08-22 |
Merck Patent Gmbh |
Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica.
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
JP7202185B2
(ja)
|
2016-12-22 |
2023-01-11 |
第一三共株式会社 |
抗cd3抗体及び該抗体を含む分子
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
DK3565592T3
(da)
|
2017-01-06 |
2023-05-01 |
Scholar Rock Inc |
Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
US20180244785A1
(en)
|
2017-01-09 |
2018-08-30 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
SG11201906554RA
(en)
|
2017-01-17 |
2019-08-27 |
Daiichi Sankyo Co Ltd |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
AU2017396503A1
(en)
|
2017-01-30 |
2019-07-11 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis
|
AU2017398101A1
(en)
|
2017-02-07 |
2019-08-01 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
CN110462038A
(zh)
|
2017-02-07 |
2019-11-15 |
第一三共株式会社 |
抗gprc5d抗体和包含所述抗体的分子
|
MX2019009498A
(es)
|
2017-02-08 |
2019-10-02 |
Novartis Ag |
Anticuerpos mimeticos de fgf21 y usos de los mismos.
|
BR112019016374A2
(pt)
|
2017-02-17 |
2020-04-07 |
Bristol-Myers Squibb Company |
anticorpos para alfa-sinucleína e usos dos mesmos
|
TWI781145B
(zh)
|
2017-02-28 |
2022-10-21 |
美商伊繆諾金公司 |
具有自分解肽連接子之類美登素衍生物及其結合物
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
EP3595682A1
(de)
|
2017-03-13 |
2020-01-22 |
Poseida Therapeutics, Inc. |
Zusammensetzungen und verfahren zum selektiven eliminieren und ersetzen von hämatopoietischen stammzellen
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
EP3604340A4
(de)
|
2017-03-24 |
2021-01-06 |
Zenyaku Kogyo Co., Ltd |
Anti-igm/b-zelloberflächenantigen-bispezifischer antikörper
|
WO2018175460A1
(en)
|
2017-03-24 |
2018-09-27 |
Novartis Ag |
Methods for preventing and treating heart disease
|
CN110741017B
(zh)
|
2017-03-30 |
2023-08-29 |
约翰霍普金斯大学 |
用于纯化生物大分子的超分子高亲和力蛋白结合系统
|
US11254733B2
(en)
|
2017-04-07 |
2022-02-22 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza B virus neuraminidase antibodies and uses thereof
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
US10877048B2
(en)
|
2017-04-15 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
EP3612560A1
(de)
|
2017-04-21 |
2020-02-26 |
Staten Biotechnology B.V. |
Anti-apoc3-antikörper und verfahren zur verwendung davon
|
KR102637960B1
(ko)
|
2017-04-22 |
2024-02-21 |
이뮤노믹 쎄라퓨틱스, 인크. |
개선된 lamp 구축물
|
JP7080899B2
(ja)
|
2017-04-28 |
2022-06-06 |
アボット・ラボラトリーズ |
同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
JP7222915B2
(ja)
|
2017-05-02 |
2023-02-15 |
イミュノミック セラピューティックス, インコーポレイテッド |
癌抗原を含む改善されたlamp構築物
|
EP3620531A4
(de)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
BR112019024701A2
(pt)
|
2017-05-25 |
2020-06-09 |
Abbott Lab |
métodos para auxiliar na determinação se um exame de imagem deve ser realizado em um indivíduo humano que sofreu ou pode ter sofrido uma lesão na cabeça com o uso de biomarcadores precoces
|
CA3059601A1
(en)
|
2017-05-30 |
2018-12-06 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
KR20200014379A
(ko)
|
2017-06-05 |
2020-02-10 |
얀센 바이오테크 인코포레이티드 |
비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
CN110997718B
(zh)
|
2017-06-07 |
2023-11-10 |
菲洛根股份公司 |
血管内皮生长因子/抗纤连蛋白抗体融合蛋白
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2019003104A1
(en)
|
2017-06-28 |
2019-01-03 |
Novartis Ag |
METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
|
JP7181535B2
(ja)
|
2017-06-30 |
2022-12-01 |
国立大学法人北海道大学 |
成長障害を生じない小児骨粗鬆症治療薬
|
US11169159B2
(en)
|
2017-07-03 |
2021-11-09 |
Abbott Laboratories |
Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
WO2019012015A1
(en)
|
2017-07-12 |
2019-01-17 |
Iontas Limited |
POTASIC CHANNEL INHIBITORS
|
GB201711208D0
(en)
|
2017-07-12 |
2017-08-23 |
Iontas Ltd |
Ion channel inhibitors
|
KR20200027522A
(ko)
|
2017-07-13 |
2020-03-12 |
에프. 호프만-라 로슈 아게 |
Pivka에 대한 신규 결합제 및 어세이
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
MX2020000966A
(es)
|
2017-07-27 |
2020-09-28 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-cd147.
|
SG11202000634UA
(en)
|
2017-07-27 |
2020-02-27 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
MA49690A
(fr)
|
2017-07-28 |
2021-05-19 |
Scholar Rock Inc |
Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
EP3444275A1
(de)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoklonaler antikörper anti-fgfr4
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
EP3668640A4
(de)
|
2017-08-18 |
2021-07-14 |
The Johns Hopkins University |
Supramolekulare filamentöse anordnungen zur proteinreinigung
|
KR20200038303A
(ko)
|
2017-08-18 |
2020-04-10 |
캠브리지 엔터프라이즈 리미티드 |
모듈형 결합 단백질
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
SG11202001813UA
(en)
|
2017-08-28 |
2020-03-30 |
Shanghai Yile Biotechnology Co Ltd |
Polypeptide and antibody bound to polypeptide
|
CN111727256A
(zh)
|
2017-09-08 |
2020-09-29 |
波赛达治疗公司 |
用于嵌合配体受体(clr)-介导的条件性基因表达的组合物和方法
|
WO2019055780A1
(en)
*
|
2017-09-14 |
2019-03-21 |
Alere San Diego Inc. |
POLYMERASE RECOMBINASE AMPLIFICATION DETECTION USING DOUBLE HAPTEN PROBE
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
KR20200061376A
(ko)
|
2017-09-29 |
2020-06-02 |
다이이찌 산쿄 가부시키가이샤 |
항체-피롤로벤조디아제핀 유도체 콘쥬게이트
|
US20200262917A1
(en)
|
2017-10-05 |
2020-08-20 |
Daiichi Sankyo Company, Limited |
Composition for cytotoxic t cell depletion
|
JP7230819B2
(ja)
|
2017-10-06 |
2023-03-01 |
小野薬品工業株式会社 |
二重特異性抗体
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
JP7235249B2
(ja)
|
2017-10-20 |
2023-03-08 |
学校法人兵庫医科大学 |
抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
BR112020008514A2
(pt)
|
2017-10-31 |
2020-10-20 |
Staten Biotechnology B.V. |
anticorpos anti-apoc3 e métodos de uso dos mesmos
|
WO2019089832A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
TW201922294A
(zh)
|
2017-10-31 |
2019-06-16 |
美商伊繆諾金公司 |
抗體-藥物結合物與阿糖胞苷之組合治療
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
CA3083345A1
(en)
|
2017-11-27 |
2019-05-31 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
BR112020010248A2
(pt)
|
2017-11-28 |
2020-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação do ligante tendo atividade de ligação do ligante ajustável
|
PL3717011T3
(pl)
|
2017-11-29 |
2023-03-27 |
Csl Limited |
Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
|
JP2021505172A
(ja)
|
2017-12-06 |
2021-02-18 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
造血幹細胞及び前駆細胞を動員させるための投薬レジメン
|
WO2019113525A2
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
JP7379165B2
(ja)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
|
MX2020006372A
(es)
|
2017-12-19 |
2020-09-03 |
Univ Rockefeller |
Variantes de dominio de fc de igg humana con funcion efectora mejorada.
|
EP3502139A1
(de)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antikörper gegen tumorantigene
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
US11793885B2
(en)
|
2017-12-28 |
2023-10-24 |
Immunogen, Inc. |
Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
|
KR20200106525A
(ko)
|
2018-01-05 |
2020-09-14 |
에이씨 이뮨 에스.에이. |
미스폴딩된 tdp-43 결합 분자
|
EP3508499A1
(de)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antikörper zum targeting von, und andere modulatoren von, einem immunglobulingen im zusammenhang mit resistenz gegen antitumor-immunantworten und verwendungen davon
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
US20210363238A1
(en)
|
2018-01-31 |
2021-11-25 |
Motokazu Kato |
Therapeutic agent for asthma containing il-6 inhibitor
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
TW202340257A
(zh)
|
2018-02-09 |
2023-10-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
BR112020016400A2
(pt)
|
2018-02-14 |
2020-12-15 |
Viela Bio, Inc. |
Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
|
US11591399B2
(en)
|
2018-02-14 |
2023-02-28 |
Abba Therapeutics Ag |
Anti-human PD-L2 antibodies
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
CN111971308A
(zh)
|
2018-03-02 |
2020-11-20 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
AU2019232624A1
(en)
|
2018-03-05 |
2020-09-10 |
Janssen Biotech, Inc. |
Methods of treating Crohn's disease with anti-IL23 specific antibody
|
CA3093205A1
(en)
|
2018-03-05 |
2019-09-12 |
Saitama Medical University |
Pharmaceutical composition for treating or preventing heterotopic ossification
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
EP3765497A1
(de)
|
2018-03-14 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Neuartige anti-troponin-t-antikörper
|
MX2020009568A
(es)
|
2018-03-14 |
2022-03-28 |
Surface Oncology Inc |
Anticuerpos que se unen a cd39 y sus usos.
|
WO2019175131A1
(en)
|
2018-03-14 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Method for affinity maturation of antibodies
|
WO2019183499A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
CN111886256A
(zh)
|
2018-03-23 |
2020-11-03 |
百时美施贵宝公司 |
抗mica和/或micb抗体及其用途
|
US20210009632A1
(en)
|
2018-03-29 |
2021-01-14 |
Bristol-Myers Squibb Company |
Methods of purifying monomeric monoclonal antibodies
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
CN112585165A
(zh)
|
2018-04-25 |
2021-03-30 |
普罗米修斯生物科学公司 |
优化的抗tl1a抗体
|
WO2019207159A1
(en)
|
2018-04-27 |
2019-10-31 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
US11065336B2
(en)
|
2018-04-30 |
2021-07-20 |
Medimmune Limited |
Conjugates for targeting and clearing aggregates
|
MA52590A
(fr)
|
2018-05-11 |
2021-03-17 |
Janssen Biotech Inc |
Méthodes de traitement de la dépression à l'aide d'anticorps il-23
|
TW202003048A
(zh)
|
2018-05-15 |
2020-01-16 |
美商伊繆諾金公司 |
用抗體-藥物偶聯物及flt3抑制劑之組合治療
|
US20210261647A1
(en)
|
2018-05-15 |
2021-08-26 |
Immunomic Therapeutics, Inc |
Lamp constructs comprising allergens
|
BR112020023187A2
(pt)
|
2018-05-16 |
2021-04-20 |
Janssen Biotech, Inc. |
métodos para tratamento de cânceres e de aumento da eficácia de agentes terapêuticos de redirecionamento de células t
|
WO2019225568A1
(ja)
|
2018-05-21 |
2019-11-28 |
中外製薬株式会社 |
ガラス容器に封入された凍結乾燥製剤
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
KR20210015902A
(ko)
|
2018-05-24 |
2021-02-10 |
얀센 바이오테크 인코포레이티드 |
Psma 결합제 및 이의 용도
|
SG11202011270QA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Anti-cd3 antibodies and uses thereof
|
BR112020023416A2
(pt)
|
2018-05-24 |
2021-02-17 |
Janssen Biotech, Inc. |
anticorpos anti-tmeff2 monoespecíficos e multiespecíficos e usos dos mesmos
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CA3102743A1
(en)
|
2018-06-18 |
2019-12-26 |
UCB Biopharma SRL |
Gremlin-1 antagonist for the prevention and treatment of cancer
|
WO2019246494A1
(en)
|
2018-06-21 |
2019-12-26 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
US20210277118A1
(en)
|
2018-06-21 |
2021-09-09 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3833442A2
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antikörper zur bindung von cd277 und verwendungen davon
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
EP3849602A1
(de)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombination eines her2/neu-antikörpers mit häm zur behandlung von krebs
|
EP3883606B9
(de)
|
2018-09-24 |
2023-10-04 |
Janssen Biotech, Inc. |
Sichere und wirksame methode zur behandlung von colitis ulcerosa mit anti-il12/il23-antikörper
|
AU2019349958A1
(en)
|
2018-09-28 |
2021-05-06 |
Kyowa Kirin Co., Ltd. |
IL-36 antibodies and uses thereof
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP2022512722A
(ja)
|
2018-10-17 |
2022-02-07 |
ヤンセン バイオテツク,インコーポレーテツド |
抗cd38抗体の皮下投与を提供する方法
|
EA202191122A1
(ru)
|
2018-10-23 |
2021-07-19 |
Сколар Рок, Инк. |
СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
AU2019367206A1
(en)
|
2018-10-25 |
2021-05-27 |
Jjp Biologics Sp. Z O.O. |
Anti-human CD89 antibodies and uses thereof
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
US20210403546A1
(en)
|
2018-11-05 |
2021-12-30 |
Ludwig Institute For Cancer Research Ltd. |
Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
|
AU2019374496A1
(en)
|
2018-11-05 |
2021-05-27 |
Centre Hospitalier Universitaire Vaudois |
Humanized and variant TGF-β3 specific antibodies and methods and uses thereof
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
BR112021009251A2
(pt)
|
2018-11-14 |
2021-08-10 |
Daiichi Sankyo Company, Limited |
conjugado anticorpo-fármaco, anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para produção de um anticorpo com glicano remodelado, de um conjugado anticorpo-fármaco, do anticorpo ou um fragmento funcional do mesmo e para tratamento de um tumor.
|
EP3880708A1
(de)
|
2018-11-16 |
2021-09-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a-antikörper und verwendungen davon
|
KR20210093974A
(ko)
|
2018-11-20 |
2021-07-28 |
가부시키가이샤 페르세우스 프로테오믹스 |
세포내 철 흡수 억제제
|
JP7463366B2
(ja)
|
2018-11-20 |
2024-04-08 |
タケダ ワクチン,インコーポレイテッド |
新規の抗ジカウイルス抗体及びその使用
|
CN113395979A
(zh)
|
2018-11-20 |
2021-09-14 |
詹森生物科技公司 |
用抗il-23特异性抗体治疗银屑病的安全且有效的方法
|
EP3897722A4
(de)
|
2018-12-18 |
2022-09-14 |
Janssen Biotech, Inc. |
Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
|
US20220042038A1
(en)
|
2018-12-20 |
2022-02-10 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
CA3124356A1
(en)
|
2018-12-20 |
2020-06-25 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
CN113227135A
(zh)
|
2018-12-28 |
2021-08-06 |
斯帕克斯治疗公司 |
用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
MX2021008453A
(es)
|
2019-01-16 |
2021-08-19 |
Compass Therapeutics Llc |
Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
CA3127236A1
(en)
|
2019-01-22 |
2020-07-30 |
Bristol-Myers Squibb Company |
Antibodies against il-7r alpha subunit and uses thereof
|
MA54814A
(fr)
|
2019-01-23 |
2021-12-01 |
Janssen Biotech Inc |
Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
AU2019427766A1
(en)
|
2019-01-30 |
2021-09-16 |
Nomocan Pharmaceuticals Llc |
Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
|
BR112021015056A2
(pt)
|
2019-01-30 |
2022-01-11 |
Scholar Rock Inc |
Inibidores específicos de complexos ltbp de tgf-beta e usos dos mesmos
|
WO2020169840A1
(en)
|
2019-02-21 |
2020-08-27 |
Cambridge Enterprise Limited |
Bispecific proteins with a chimeric scaffold
|
GB201902392D0
(en)
|
2019-02-21 |
2019-04-10 |
Cambridge Entpr Ltd |
Modular binding proteins
|
WO2020176497A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
CA3130909A1
(en)
|
2019-02-28 |
2020-09-03 |
Juntendo Educational Foundation |
Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
|
WO2020183270A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
US20200291107A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
US20220153829A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
CN113853385A
(zh)
|
2019-03-18 |
2021-12-28 |
詹森生物科技公司 |
用抗il12/il23抗体治疗儿科受试者的银屑病的方法
|
EP3943108A4
(de)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
|
US20220177601A1
(en)
|
2019-03-25 |
2022-06-09 |
Daiichi Sankyo Company, Limited |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
EP3947446A1
(de)
|
2019-03-25 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
|
KR20210143237A
(ko)
|
2019-03-25 |
2021-11-26 |
다이이찌 산쿄 가부시키가이샤 |
항체-피롤로벤조디아제핀 유도체 컨쥬게이트
|
WO2020193718A1
(en)
|
2019-03-27 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Recombinant proteins with cd40 activating properties
|
WO2020196712A1
(ja)
|
2019-03-27 |
2020-10-01 |
第一三共株式会社 |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲートとparp阻害剤の組み合わせ
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
WO2020205469A1
(en)
|
2019-03-29 |
2020-10-08 |
Bristol-Myers Squibb Company |
Methods of measuring hydrophobicity of chromatographic resins
|
TW202102544A
(zh)
|
2019-04-04 |
2021-01-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
EP3954696A4
(de)
|
2019-04-10 |
2023-07-26 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur reinigung von fc-region-modifiziertem antikörper
|
JP2022529943A
(ja)
|
2019-04-15 |
2022-06-27 |
クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー |
がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
|
TW202110477A
(zh)
|
2019-04-17 |
2021-03-16 |
國立大學法人廣島大學 |
以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
|
MX2021012767A
(es)
|
2019-04-19 |
2021-11-18 |
Janssen Biotech Inc |
Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
|
EP3958908A1
(de)
|
2019-04-24 |
2022-03-02 |
Heidelberg Pharma Research GmbH |
Amatoxin-antikörper-wirkstoff-konjugate und verwendungen davon
|
SG11202111824UA
(en)
|
2019-04-30 |
2021-11-29 |
Larimar Therapeutics Inc |
Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
|
JP2022534020A
(ja)
|
2019-05-23 |
2022-07-27 |
ヤンセン バイオテツク,インコーポレーテツド |
Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
|
TW202110879A
(zh)
|
2019-05-23 |
2021-03-16 |
瑞士商Ac 免疫有限公司 |
抗tdp-43結合分子及其用途
|
SG11202112429PA
(en)
|
2019-05-29 |
2021-12-30 |
Daiichi Sankyo Co Ltd |
Dosage of an antibody-drug conjugate
|
WO2020245677A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
KR20220017430A
(ko)
|
2019-06-05 |
2022-02-11 |
추가이 세이야쿠 가부시키가이샤 |
항체 절단 부위 결합 분자
|
UY38747A
(es)
|
2019-06-12 |
2021-01-29 |
Novartis Ag |
Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
|
US20220372138A1
(en)
|
2019-07-05 |
2022-11-24 |
Iomx Therapeutics Ag |
Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
|
TW202328206A
(zh)
|
2019-07-05 |
2023-07-16 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
CN114144436A
(zh)
|
2019-07-24 |
2022-03-04 |
H.隆德贝克有限公司 |
抗mGluR5抗体及其用途
|
JPWO2021020282A1
(de)
|
2019-07-26 |
2021-02-04 |
|
|
EP4008348A4
(de)
|
2019-07-30 |
2023-11-15 |
ONO Pharmaceutical Co., Ltd. |
Bispezifische antikörper
|
EP4011918A4
(de)
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
Dual-spezifisches protein
|
AU2020329217A1
(en)
|
2019-08-12 |
2022-07-28 |
Aptevo Research And Development Llc |
4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
BR112022003740A2
(pt)
|
2019-08-30 |
2022-05-31 |
Agenus Inc |
Anticorpos anti-cd96 e métodos de uso dos mesmos
|
EP4026560A4
(de)
|
2019-09-04 |
2023-10-25 |
Perseus Proteomics Inc. |
Therapeutisches mittel für polyzythämie
|
CN114641501A
(zh)
|
2019-09-04 |
2022-06-17 |
Y生物股份有限公司 |
抗vsig4抗体或抗原结合片段及其用途
|
JP2022547866A
(ja)
|
2019-09-05 |
2022-11-16 |
ポセイダ セラピューティクス,インコーポレイティド |
同種異系細胞組成物と使用方法
|
CN114450024A
(zh)
|
2019-09-16 |
2022-05-06 |
表面肿瘤学公司 |
抗cd39抗体组合物和方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
EP4031578A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
|
US20210115127A1
(en)
|
2019-09-25 |
2021-04-22 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
JP2022549504A
(ja)
|
2019-09-26 |
2022-11-25 |
エスティーキューブ アンド カンパニー |
グリコシル化ctla-4に対して特異的な抗体およびその使用方法
|
JP2022550325A
(ja)
|
2019-09-27 |
2022-12-01 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
抗ミュラー管抑制物質抗体およびその使用
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
WO2021066869A1
(en)
|
2019-10-04 |
2021-04-08 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
US11628222B2
(en)
|
2019-10-14 |
2023-04-18 |
Aro Biotherapeutics Company |
CD71 binding fibronectin type III domains
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
KR20220083773A
(ko)
|
2019-10-18 |
2022-06-20 |
이뮤노믹 쎄라퓨틱스, 인크. |
암 항원을 포함하는 개선된 lamp 구축물
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
JP2022553324A
(ja)
|
2019-10-24 |
2022-12-22 |
プロメテウス バイオサイエンシーズ,インク. |
Tnf様リガンド1a(tl1a)に対するヒト化抗体およびその使用
|
CA3155172A1
(en)
|
2019-10-25 |
2021-04-29 |
Shinko HAYASHI |
Combination of anti-garp antibody and immunomodulator
|
WO2021087406A1
(en)
|
2019-11-01 |
2021-05-06 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progentor cells
|
WO2021090146A1
(en)
|
2019-11-04 |
2021-05-14 |
Astrazeneca Ab |
Combination therapy for treating cancer
|
EP3822288A1
(de)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Gegen das cd276-antigen gerichtete antikörper, und andere modulatoren gegen das cd276-antigen, und deren verwendung
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
calr and jak2 mutant-based vaccines and their uses
|
WO2021099576A1
(en)
|
2019-11-21 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
|
WO2021107082A1
(ja)
|
2019-11-27 |
2021-06-03 |
株式会社ペルセウスプロテオミクス |
癌性腹膜炎の治療薬
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
AU2020408213A1
(en)
|
2019-12-19 |
2022-06-23 |
Quidel Corporation |
Monoclonal antibody fusions
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
JP2023510121A
(ja)
|
2019-12-20 |
2023-03-13 |
ポセイダ セラピューティクス,インコーポレイティド |
抗Muc1組成物及び使用方法
|
KR20220128363A
(ko)
|
2019-12-24 |
2022-09-20 |
제이제이피 바이오로직스 에스피. 제트 오.오. |
항-인간 hvem(tnfrsf14) 항체 및 그의 용도
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
BR112022011749A2
(pt)
|
2020-01-06 |
2022-08-30 |
Vaccinex Inc |
Anticorpos anti-ccr8 e seus usos
|
CN115052663A
(zh)
|
2020-01-08 |
2022-09-13 |
辛瑟斯治疗股份有限公司 |
Alk5抑制剂缀合物及其用途
|
CA3165713A1
(en)
|
2020-01-30 |
2021-08-05 |
Andrew Scharenberg |
Bispecific transduction enhancer
|
US20230061973A1
(en)
|
2020-02-05 |
2023-03-02 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
US20230151109A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
US20230151108A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
EP4103610A1
(de)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Anti-cd4-ctla4 bispezifische antikörper
|
WO2021160267A1
(en)
|
2020-02-13 |
2021-08-19 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
EP4103611B1
(de)
|
2020-02-13 |
2024-03-27 |
UCB Biopharma SRL |
Bispezifische, an hvem und cd9 bindende antikörper
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
US20230220074A1
(en)
|
2020-02-18 |
2023-07-13 |
Alector Llc |
Pilra antibodies and methods of use thereof
|
WO2021178896A1
(en)
|
2020-03-06 |
2021-09-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2021176424A1
(en)
|
2020-03-06 |
2021-09-10 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
AU2021232853A1
(en)
|
2020-03-10 |
2022-09-22 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
WO2021183795A1
(en)
|
2020-03-11 |
2021-09-16 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
EP4129333A1
(de)
|
2020-03-27 |
2023-02-08 |
PhotoQ3 Inc. |
Pharmazeutisches arzneimittel zur zerstörung von tumorzellen
|
IL296514A
(en)
|
2020-03-30 |
2022-11-01 |
Univ Mie |
Bispecific antibody
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
CN115379858A
(zh)
|
2020-04-06 |
2022-11-22 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
JP2023521178A
(ja)
|
2020-04-10 |
2023-05-23 |
バヌディス ゲーエムベーハー |
予防および治療における自然抗体
|
EP4136459A1
(de)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
|
CA3174777A1
(en)
|
2020-04-14 |
2021-10-21 |
Eric M. Ostertag |
Compositions and methods for use in the treatment of cancer
|
MX2022013085A
(es)
|
2020-04-21 |
2023-01-11 |
Jjp Biologics Sp Z O O |
Anticuerpos cd89 anti-humanos humanizados y usos de los mismos.
|
EP4143302A1
(de)
|
2020-04-27 |
2023-03-08 |
Magenta Therapeutics, Inc. |
Verfahren und zusammensetzungen zur transduktion hämatopoetischer stamm- und vorläuferzellen in vivo
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
WO2021220218A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Immunoglobulin variants
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
US20230183366A1
(en)
|
2020-05-13 |
2023-06-15 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Recombinant proteins with ox40 activating properties
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
WO2021233834A1
(en)
|
2020-05-17 |
2021-11-25 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
WO2021261546A1
(ja)
|
2020-06-24 |
2021-12-30 |
国立大学法人 東京大学 |
光増感色素
|
US20240010720A1
(en)
|
2020-07-06 |
2024-01-11 |
Iomx Therapeutics Ag |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
MX2023000547A
(es)
|
2020-07-16 |
2023-02-13 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
|
IL299757A
(en)
|
2020-07-20 |
2023-03-01 |
Astrazeneca Uk Ltd |
SARS-COV-2 proteins, antibodies against SARS-COV-2, and methods of using them
|
EP4190354A1
(de)
|
2020-07-28 |
2023-06-07 |
Chugai Seiyaku Kabushiki Kaisha |
Vorgefüllte spritzenzubereitung mit nadel mit nadelschutz und mit neuartigem modifiziertem antikörper
|
WO2022022662A1
(zh)
|
2020-07-31 |
2022-02-03 |
百奥泰生物制药股份有限公司 |
Cd47抗体及其应用
|
JPWO2022025220A1
(de)
|
2020-07-31 |
2022-02-03 |
|
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
WO2022032020A1
(en)
|
2020-08-07 |
2022-02-10 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting cd46 and methods of use thereof
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
CN116761821A
(zh)
|
2020-08-18 |
2023-09-15 |
赛福伦有限责任公司 |
抗par-2抗体及其使用方法
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
EP4204448A2
(de)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2-antikörper zur makrophagen- und dendritischen zelldifferenzierung
|
JPWO2022045247A1
(de)
|
2020-08-27 |
2022-03-03 |
|
|
WO2022047359A1
(en)
|
2020-08-31 |
2022-03-03 |
Berg Llc |
Protein biomarkers for pancreatic cancer
|
JP2023540082A
(ja)
|
2020-09-04 |
2023-09-21 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
SARS-CoV-2ワクチン及び抗体
|
AU2021339953A1
(en)
|
2020-09-11 |
2023-05-18 |
Medimmune Limited |
Therapeutic b7-h4 binding molecules
|
AU2021342349A1
(en)
|
2020-09-12 |
2023-05-25 |
Medimmune Limited |
A scoring method for an anti-b7h4 antibody-drug conjugate therapy
|
CN116472282A
(zh)
|
2020-10-08 |
2023-07-21 |
国立大学法人东海国立大学机构 |
抗转铁蛋白受体抗体的药效或感受性的判定方法
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
AU2021359092A1
(en)
|
2020-10-15 |
2023-06-01 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
AU2021366287A1
(en)
|
2020-10-20 |
2023-04-13 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
EP3992205A1
(de)
|
2020-11-03 |
2022-05-04 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Verbindung zum binden des sars coronavirus-2 spike-proteins
|
WO2022096536A1
(en)
|
2020-11-03 |
2022-05-12 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
US20230406921A1
(en)
|
2020-11-12 |
2023-12-21 |
Mabwell (shanghai) Bioscience Co., Ltd. |
Antibody and preparation method therefor
|
WO2022106205A1
(en)
|
2020-11-18 |
2022-05-27 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Corona virus spike protein binding compounds
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20240052042A1
(en)
|
2020-12-14 |
2024-02-15 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
|
EP4271998A1
(de)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
|
US20240115720A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
JP2024503658A
(ja)
|
2021-01-13 |
2024-01-26 |
メモリアル スローン-ケタリング キャンサー センター |
抗dll3抗体-薬物コンジュゲート
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
EP4284422A1
(de)
|
2021-01-28 |
2023-12-06 |
Vaccinvent GmbH |
Verfahren und mittel zur modulation von b-zell-vermittelten immunantworten
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
EP4284838A2
(de)
|
2021-01-28 |
2023-12-06 |
Janssen Biotech, Inc. |
Psma-bindende proteine und verwendungen davon
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
TW202302645A
(zh)
|
2021-03-03 |
2023-01-16 |
法商皮爾法伯製藥公司 |
抗vsig4抗體或抗原結合片段及其用途
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
KR20230156387A
(ko)
|
2021-03-12 |
2023-11-14 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
|
CA3213278A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
KR20230156368A
(ko)
|
2021-03-12 |
2023-11-14 |
추가이 세이야쿠 가부시키가이샤 |
중증 근무력증의 치료 또는 예방용의 의약 조성물
|
EP4308694A1
(de)
|
2021-03-16 |
2024-01-24 |
Magenta Therapeutics, Inc. |
Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
|
AU2022236492A1
(en)
|
2021-03-18 |
2023-10-26 |
Medimmune Limited |
Therapeutic binding molecule that binds to ccr9
|
EP4317435A1
(de)
|
2021-03-29 |
2024-02-07 |
Daiichi Sankyo Company, Limited |
Stabiles multispezifisches molekül und verwendung davon
|
EP4067381A1
(de)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Neue tnfr2-bindende moleküle
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
IL307530A
(en)
|
2021-04-06 |
2023-12-01 |
Bpgbio Inc |
Estrogen receptor-like (ER) breast cancer protein markers LUMINAL A (LA) and LUMINAL B1 (LB1)
|
WO2022216846A1
(en)
|
2021-04-06 |
2022-10-13 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
IL307528A
(en)
|
2021-04-06 |
2023-12-01 |
Bpgbio Inc |
Protein markers for the prognosis of breast cancer progression
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Tcrに結合する多機能性分子およびその使用
|
CN113156121B
(zh)
*
|
2021-04-16 |
2021-12-07 |
苏州东尼生物技术有限公司 |
一种用于检测人甲状腺球蛋白的胶体金试纸条
|
BR112023022878A2
(pt)
|
2021-05-04 |
2024-01-23 |
Regeneron Pharma |
Agonistas do receptor fgf21 multiespecíficos e seus usos
|
WO2022236134A1
(en)
|
2021-05-07 |
2022-11-10 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
AU2022293389A1
(en)
|
2021-06-14 |
2024-01-04 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
AU2022292462A1
(en)
|
2021-06-18 |
2023-12-07 |
Nammi Therapeutics, Inc. |
FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
|
WO2022271867A1
(en)
|
2021-06-23 |
2022-12-29 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
WO2023281463A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
IL309997A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
WO2023288277A1
(en)
|
2021-07-14 |
2023-01-19 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgfb1 and uses thereof
|
WO2023286854A1
(ja)
|
2021-07-16 |
2023-01-19 |
ブライトパス・バイオ株式会社 |
抗Tim-3抗原抗体または抗体誘導体およびその用途
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
CA3228178A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
WO2023027164A1
(ja)
|
2021-08-26 |
2023-03-02 |
株式会社ペルセウスプロテオミクス |
Ros(活性酸素種)産生増強剤
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
TW202323289A
(zh)
|
2021-08-31 |
2023-06-16 |
日商大正製藥股份有限公司 |
抗生長激素抗體
|
AU2022339667A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
CA3230933A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
WO2023042097A1
(en)
|
2021-09-15 |
2023-03-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022360244A1
(en)
|
2021-10-04 |
2024-04-11 |
Poseida Therapeutics, Inc. |
Transposon compositions and methods of use thereof
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|
TW202333781A
(zh)
|
2021-10-08 |
2023-09-01 |
日商中外製藥股份有限公司 |
抗hla-dq2﹒5抗體製劑
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
US20230134748A1
(en)
|
2021-11-03 |
2023-05-04 |
Janssen Biotech, Inc. |
Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2023088959A1
(en)
|
2021-11-16 |
2023-05-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
WO2023090361A1
(ja)
|
2021-11-16 |
2023-05-25 |
国立大学法人鳥取大学 |
改変d領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023141576A1
(en)
|
2022-01-21 |
2023-07-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2023139293A1
(en)
|
2022-01-24 |
2023-07-27 |
Novimmune Sa |
Composition and methods for the selective activation of cytokine signaling pathways
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023166081A1
(en)
|
2022-03-02 |
2023-09-07 |
Heidelberg Immunotherapeutics Gmbh |
Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
|
US20240002544A1
(en)
|
2022-03-07 |
2024-01-04 |
Novimmune Sa |
Cd28 bispecific antibodies for targeted t cell activation
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
WO2023196937A1
(en)
|
2022-04-06 |
2023-10-12 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring frataxin replacement therapy
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240201A1
(en)
|
2022-06-08 |
2023-12-14 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024006961A1
(en)
|
2022-07-01 |
2024-01-04 |
Neoleukin Therapeutics, Inc. |
Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024050354A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|